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Introduction 
Screening 
Screening is the testing of asymptomatic individuals for a given disease with no signs or 
symptoms of the disease in question. Questions, physical exam, laboratory tests, and imaging 
are commonly used screening modalities. 1 Substantial benefits may be associated with 
screening, ideally a reduction in mortality if screening diagnoses disease at an earlier, more 
treatable stage. Earlier diagnosis of disease can also lead to decreased morbidity for these 
patients. In addition, for patients who worry about having a particular disease, a negative 
screening test may help them achieve peace of mind. 
Yet screening is also associated with potential harms, including false positives, side 
effects, and overdiagnosis. A false positive test occurs when a positive screening result occurs in 
a patient who does not actually have the disease in question. False positives may lead to 
unnecessary biopsies, further work-up, and unnecessary anxiety for the patient. A recent review 
of studies that assessed the long-term effects of false positive mammograms found that women 
receiving a false positive diagnosis of breast cancer by mammogram were significantly more 
likely to experience worry, intrusive thoughts, and anxiety specific to breast cancer than women 
who received normal diagnoses.2 Screening itself can lead to side effects, for example, in 
prostate cancer screening with digital rectal exam, the test itself can lead to a great deal of 
anxiety, whether results are positive or negative. In colon cancer screening with colonoscopy, 
scoping results in a ruptured colon in about 1-2 in every I 000 screened patients. 3• 4 A third risk 
of screening, particularly screening in older populations, is overdiagnosis. 
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Overdiagnosis 
Overdiagnosis is the diagnosis by screening of cancers that would have never become 
clinically meaningful in the absence of screening. This can occur in two ways: either screening 
detects cancer that is non-progressive or progresses so slowly that it never causes patient 
morbidity, or screening detects cancer at a time in the patient's life when the patient is old 
enough or sick enough that he/she will die of another disease before the cancer causes significant 
morbidity5 Similar to false positives, overdiagnosis can lead to unnecessary biopsies, 
unnecessary treatments, and adverse effects. All of these excess diagnostic and therapeutic 
measures lead to increased costs that affect both the patient and the health care system as a 
whole. The risk of overdiagnosis is higher in the elderly because they have more comorbidities 
which contribute to overall mortality. 
Figure 1: Number of Cases of Disease in the Presence and Absence of Screening*" 
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Overdiagnosis due to screening can be measured by comparing rates of disease in 
screened and unscreened cohorts of patients over a period of time. Figure 1 shows a hypothetical 
study in which an identical number of patients from a given population were randomly selected 
for yearly screening or no screening. Both groups initially have 1000 cases of disease per year. 
This model assumes that the baseline incidence of disease is not changing in the population, and 
thus the unscreened group continues to have 1000 cases of disease per year. However, when the 
screening program is initiated in year 3, a large peak in the number of incident cases occurs in 
the screened group due to screening finding many of the prevalent cases of disease in the 
population. These cases developed over the lifetime of the patients being screened, and after this 
initial increase in incidence, the number of cases declines as fewer and fewer prevalent cases are 
picked up by screening. 
This decline continues until a period of time equivalent to the lead time has passed since 
the initiation of screening. The lead time is the amount of time by which screening advances 
diagnosis. Thus if screening can detect disease 5 years before detectible symptoms of the disease 
develop, the disease has a lead time of 5 years. At the end of the lead time from initial screening, 
the number of cases in the screened group should be identical to the number of cases in the 
unscreened group: all of the prevalent cases should have been detected by this time, and thus 
screening should be detecting each case as it arises 5 years before it would have become 
clinically symptomatic. Yet in figure I, the number of cases continues to be higher in the 
screened group than the unscreened group after the 5-year lead time has passed. This 
discrepancy of 500 cases is due to overdiagnosis: these cases are those that would have never 
come to clinical attention because the patient would have died of comorbid diseases whether they 
had been screened or not before the disease in question could become symptomatic. These 
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patients would have never been diagnosed in the absence of screening and any treatment or 
further diagnostic tests for their disease would thus be unnecessary. 
Yet figure I is a simplified example of overdiagnosis; in reality, the situation can be 
much more complicated. First of all, the baseline incidence of most diseases does not remain 
stable over time. The incidence of breast cancer, for example, gradually increased from 1980 to 
2000 and has since leveled off6 If the baseline incidence were increasing over time in the above 
example, the incidence of disease in the unscreened group would increase over time. The 
incidence of disease in the screened group would increase by this baseline amount plus whatever 
increased diagnosis occurred due to detection of prevalent cases and overdiagnosis. Another 
assumption that the above example does not take into account is the possibility of contamination 
in the unscreened group. Many screening tests are so widespread that it is difficult to prevent 
opportunistic screening to occur in the control group. In this case, the incidence in the control 
l,'fOup would seem higher than the actual incidence, and thus the amount of overdiagnosis left 
over at the end of the study would be underestimated. In addition, the lead time of a screening 
test is hard to estimate with accuracy. Diseases that have a range of clinical manifestations, such 
as those in which some cases are aggressive and others are less so, tend to have a range of lead 
times. More aggressive disease has a shorter lead time than less aggressive disease. Most 
diseases have a range of possible lead times depending on the aggressiveness of the disease, 
which makes it difficult to predict the point at which excess cases above baseline are due to 
overdiagnosis alone. 
Why is Overdiagnosis a Significant Problem 
Overdiagnosis is a particular concern in cancer screening for this reason. Many cancers 
are so slow growing that it will take many years for the patient to develop clinical disease. 
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However, other cancers are extremely aggressive and clinical disease develops in a short period 
of time. Unfortunately, screening disproportionately detects slower growing cancers due to the 
longer lead time during which the patient has disease. This phenomenon is known as length-time 
bias. 1 An extreme form of length-time bias is in effect in the type of overdiagnosis in which a 
screen-diagnosed cancer would never have been diagnosed because the cancer is growing so 
slowly that it would have never caused symptoms. Patients with slow growing cancers, therefore, 
are at high risk of overdiagnosis and subsequent overtreatrnent. This risk is enhanced in the 
elderly, who are at high risk for many types of cancers. The risk of overdiagnosis is concerning 
for two types of cancer in particular-prostate cancer and breast cancer-because each has a 
significant proportion of slow growing cancers, screening is fairly widespread, and the elderly 
are those who are most commonly screened. 
Prostate Cancer Screening 
Prostate cancer is the most common cancer in US males; the American Cancer Society 
estimates that 218,890 new cases will occur in 2007. It is the second leading cause of cancer 
death in males with 27,050 deaths estimated by the ACS to occur in 2007.6 Currently, screening 
for prostate cancer occurs by serum prostate-specific antigen (PSA) level and digital rectal exam 
(ORE). Thus far, the evidence is inconclusive as to whether the benefits of screening outweigh 
the risks. In their most recent review of the literature, the United States Preventive Services Task 
Force (USPSTF) concluded that the evidence was insufficient to recommend for or against 
routine PSA or ORE screening.7• 8 The primary potential benefits of screening include decreased 
morbidity and mortality due to prostate cancer. Previous studies have shown conflicting results 
as to whether screening decreases prostate cancer mortality. 9' 12 Two large randomized 
controlled trials on the topic, the European Randomized Study of Screening for Prostate Cancer 
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(ERSPC) and the U.S. National Cancer Institute "Prostate, Lung, Colorectal, and Ovary" Trial 
(PLCO), are currently underway, but data on mortality will not be available for a few years. 
Screening is associated with potential harms as well. PSA screening for prostate cancer 
is less specific in men at high risk for benign prostatic hyperplasia, thus false positives are one 
potential risk, especially in older populations. This can lead to unnecessary biopsies, increased 
anxiety, and even unnecessary treatment with prostatectomy, radiation, or androgen deprivation 
and the adverse effects that result from these therapies. Overdiagnosis is another worrisome risk 
of prostate cancer screening. 
Overdiagnosis is particularly concerning in prostate cancer screening for several reasons. 
Elderly men are at high risk of developing prostate cancer, yet this population commonly has 
many other comorbidities that limit life expectancy. Thus screening in this population would 
lead to diagnosis of many patients who would never have developed clinical disease, leading to 
unnecessary biopsies, costs, and possibly treatment. In addition, much uncertainty exists 
regarding the natural history of untreated or minimally treated prostate cancer, but it is likely that 
a significant proportion of prostate cancer patients do not benefit from treatment. A prospective 
cohort study in Sweden found that 15 years after diagnosis of localized prostate cancer, survival 
rates in 223 patients who deferred treatment were similar to those who received initial treatment 
(81% 15-yr survival in both groups). 13 A follow up of this study at 20 years found that in the 
untreated patients, prostate-cancer specific survival fell from 79% at 15 years to 54% at 20 years, 
indicating that early treatment of patients with a life expectancy longer than 15 years may be 
beneficial. 14 However, another recent retrospective cohort study of767 men diagnosed with 
early stage prostate cancer and treated with observation or androgen deprivation therapy alone 
found that prostate cancer specific mortality rates dropped from 33 per 1000 patients at 15 years 
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to 18 per I 000 patients after 15 years. In this study, higher Gleason scores were correlated with 
higher prostate cancer specific mortality rates, ranging from 6 per I 000 person years for low 
grade cancers to 121 per 1000 person-years for high grade cancers. 15 
Despite the inconsistencies across these studies, they all indicate that there is a significant 
proportion of men diagnosed with prostate cancer who do not benefit from early treatment. 
Because screening preferentially detects low-grade cancers by length-time bias and treatment 
does not seem to help patients with early stage disease at 10 to 15 years of follow-up, it is likely 
that a significant amount of overdiagnosis and overtreatment occur in patients diagnosed with 
prostate cancer by screening. Moreover, it is nearly impossible to predict which patients will 
develop comorbidities and die of causes other than prostate cancer 15 years down the line. Thus 
the overall potential for overdiagnosis due to prostate cancer screening seems to be high. 
Breast Cancer Screening 
Statistically, breast cancer is comparable to prostate cancer in terms of cases and 
mortality. The ACS predicts 178,480 new cases among US women in 2007, which makes breast 
cancer the most common cancer diagnosis. In addition, it will also be the second most common 
cause of cancer-related death among women, with 40,460 predicted deaths in 2007.6 Screening 
modalities for breast cancer include mammography, clinical breast exam (CBE), and breast self-
examination (BSE). In their most recent review, the USPSTF performed a meta-analysis of7 
high quality trials and found a relative risk (RR) of dying of breast cancer of 0.84 (95% CI: 0. 77-
0.91) for women screened with mammography compared to those unscreened. 16 The USPSTF 
thus recommends screening mammography every 1-2 years for all women aged 40 and older. 
However, they found insufficient evidence to recommend for or against CBE alone for breast 
cancer screening. 17 Thus, the major benefit of breast cancer screening is a 16% relative risk 
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reduction in breast cancer mortality. Harms of screening include anxiety, discomfort, cost, and 
false positives leading to unnecessary biopsies and treatment. In addition, overdiagnosis leading 
to overtreatment, particularly in DCIS patients, is a concern. 
Some of the breast cancer cases diagnosed by screening are ductal carcinoma in situ 
(DCIS), which is a localized, slowly progressive form. One large study of over 650,000 
mammograms found that approximately 18% of breast cancer cases diagnosed by screening 
mammography were DCIS. 18 This significant proportion of women diagnosed with breast 
cancer would be at higher risk for overdiagnosis than women diagnosed with invasive cancers 
due to the more slowly progressive nature ofDCIS. In addition, the rate of diagnosis ofDCIS by 
mammography seems to increase with age with over I in every 1000 women aged 70-84 
screened by mammography diagnosed with DCIS as compared to about 1 in every 1800 women 
aged 40-49 screened by mammography diagnosed with DCIS. 18 
Some argue that treatment of DCIS leads to a reduction in the incidence of invasive 
cancers, but data on the natural progression of untreated DCIS are scarce. One study of 80 
women with untreated DCIS found that 14% developed invasive cancer after a mean follow-up 
of 17.5 years. 19 Smaller studies have suggested that up to 50% ofDCIS progresses to invasive 
breast cancer, but that half of these lesions do not show up within the lifetime of the diagnosed 
woman because a significant proportion ofDCIS cases are elderly. 20• 21 Overall, it is not clear 
what proportion of DCIS progresses to invasive breast cancer. However, in 1999 over 28% of 
women with DCIS had mastectomy, 64% had lumpectomy, and 33% had radiation.22 Thus, 
because it is slowly progressive in most cases and it is more commonly diagnosed in the elderly, 
a significant proportion of women with screen-detected DCIS appear to be at risk for 
overdiagnosis and subsequent overtreatment. In addition, it is unknown what proportion of 
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women who are screen diagnosed with invasive breast cancer, particularly elderly women with 
short life expectancies due to other comorbidities, are overdiagnosed and how much 
overtreatment occurs as a result. 
Focused Clinical Question 
Overall, overdiagnosis and overtreatment due to breast cancer and prostate cancer 
screening are undoubtedly present. The question is how much overdiagnosis and overtreatment 
actually occur. Estimates of the proportion of overdiagnosed cases due to screening have ranged 
widely, from 15.4% to 84% for prostate cancer and from 5% to 33% for breast cancer. Thus, the 
true magnitude of overdiagnosis of both prostate cancer and breast cancer is unknown. This 
review will attempt to answer the following questions: 
I. To what extent does screening for prostate cancer with serum PSA and DRE lead to 
overdiagnosis and overtreatment? 
2. To what extent does screening for breast cancer with mammography and CBE lead to 
overdiagnosis and overtreatment? 
3. What conclusions can be drawn about the problems of overdiagnosis and overtreatment 
due to screening from a comparison of prostate cancer and breast cancer screening? 
Methods 
Background 
Many different definitions have been used for overdiagnosis and overtreatment, and thus 
it is necessary to define the term that I used for this review. I defined overdiagnosis as the 
diagnosis by screening of a case of disease that would never have come to clinical attention had 
that patient not been screened. Overtreatment is thus the unnecessary treatment of one of these 
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overdiagnosed cases, leading to unnecessary adverse effects of treatment. I consider any 
intervention that occurs after the initial overdiagnosis of the case by screening overtreatment. 
For example, although a prostate biopsy is technically a diagnostic test, for the purposes ofthis 
review, a biopsy of an overdiagnosed case is considered overtreatment. I defined the population, 
interventions, and outcomes of this review and developed the list of questions noted above to 
focus my search. Tables I and 2 list all inclusion and exclusion criteria used in the review. 
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Table 1: Selection Criteria 
Selection Criteria Inclusion Criteria Exclusion Criteria 
Population Prostate Cancer • Screening high-risk subsets 
• Population-based focus on of the population 
asymptomatic adult males 
screened for prostate cancer 
Breast Cancer 
• Population-based focus on 
asymptomatic adult females 
screened for breast cancer 
Intervention Prostate Cancer Prostate Cancer 
• Screening Serum PSA • Diagnostic PSA or DRE 
and/or digital rectal exam • Free:total PSA or PSA 
doubling time 
• No unscreened comparison 
group 
Breast Cancer Breast Cancer 
• Screening mammography • Diagnostic mammography 
and/or clinical breast exam orCBE 
• No unscreened comparison 
group 
Outcome • Defines overdiagnosis as • Strictly pathological 
the diagnosis by screening definition of overdiagnosis 
of a case of disease that • No explicit numerical 
would have never come to estimate of overdiagnosis 
clinical attention in the 
absence of screening 
• Any measure of 
overdiagnosis or 
overtreatment (%, rate/1000 
pts screened, etc.) 
Prostate Cancer 
• Overtreatment due to 
prostate biopsy or treatment 
with radical prostatectomy, 
EBRT, ADT, or watchful 
waiting8 
Breast Cancer 
• Overtreatment due to breast 
biopsy or treatment with 
radical mastectomy, 
lumpectomy, chemo, and/or 
radiation16 
Study design • Systematic reviews, • Narrative Reviews 
randomized controlled • Case reports and case series 
trials, prospective and 
retrospective cohort studies, 
• Autopsy studies 
nested case-control studies 
• Modeling strategies based 
on the above types of 
studies or service screening 
studies 
12 
Search Strategy 
After developing the questions and criteria noted above, I formulated a search strategy 
using key search terms. I searched MEDLINE, the Cochrane Database, BIOS IS, and IS! Web of 
Science using the searches outlined in Tables 2 and 3 and reviewed the titles and abstracts of all 
English-language articles or translations. I pulled the articles which had a chance to fit the 
search criteria from the abstract list and read the full-text of these articles to further analyze them 
for possible inclusion. A second, independent reviewer read all titles and abstracts that I felt did 
not meet search criteria and pulled any remaining articles that he felt had a chance to meet the 
search criteria. In addition, I reviewed the reference lists of relevant review articles identified in 
the database search, the references of articles that were pulled in the database search, and the 
references of the National Cancer Institute's Physician Query Database (PDQ) summaries on 
cancer screening, breast cancer screening, and prostate cancer screening. I accessed the full-text 
of any articles identified in this way and read the articles in depth to assess whether they fit 
inclusion criteria. Figure 2 shows a flow chart of the inclusion process for prostate cancer 
studies, and Appendix I includes reasons for exclusion of pulled prostate cancer studies. Figure 
3 shows a flow chart of the inclusion process for breast cancer studies, and Appendix 2 includes 
reasons for exclusion of pulled breast cancer studies. 
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Table 2: Prostate Cancer Search Strategy and Results 
Database Search Used Total Articles Articles Pulled Articles used for 
Identified for Further Reference List 
(3/19/07) Review Search 
MEDLINE (prostate cancer OR PSA 159 Results 26"~' 21 .,_, 
OR digital rectal exam) 58 Review 
AND ( overdiagnos* OR 
over-diagnos* OR 
overtreat* OR over-treat* 
OR overdetect* OR over-
detect*) 
Cochrane (prostate cancer OR PSA 15 Results I'" 0 
Database OR digital rectal exam) 4 Cochrane Reviews 
AND (overdiagnos* OR I 0 Clinical Trials 
over-diagnos* OR I Teclrnology 
overtreat* OR over-treat* Assessment 
OR overdetect* OR over-
detect*) 
lSI Web of ("prostate cancer* 11 OR 107 Results II,_, 0 
Science "prostate neoplasm*" OR 
PSA OR "digital rectal 
exam" OR DRE) AND 
( overdiagnos* OR 
overtreat* OR 
overdetect*) 
BIOS IS ("prostate cancer*" OR 57 Results 0 I" 
11prostate neoplasm*" OR 
PSA OR "digital rectal 
exam" OR DRE) AND 
( overdiagnos* OR 
overtreat* OR 
overdetect*) 
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Table 3: Breast Cancer Search Strategy and Results 
Database Search Used Total Articles Articles Pulled Articles used for 
Identified for Further Reference List 
(3/19/07) Review Search 
MEDLIN£ (breast cancer OR breast 229 Results 34'· "· . ,_,.,, 9"'· '"'" 
cancers OR mammogra* 58 Review 
OR clinical breast exam) 
AND (overdiagnos* OR 
over-diagnos* OR 
overtreat* OR 
over-treat* OR overdetect* 
OR over-detect*) 
Cochrane (breast cancer OR breast 32 Results 5'"'"" 0 
Database cancers OR mammogra* 9 Cochrane Reviews 
OR clinical breast exam) 2 Other Reviews 
AND (overdiagnos* OR I 0 Clinical Trials 
over-diagnos* OR 4 Methods Studies 
overtreat* OR 2 Technology 
over-treat* OR overdetect* Assessments 
OR over-detect*) 5 Economic 
Evaluations 
IS! Web of ( 11breast cancer*" OR 129 Results 8 "'''·" 0 
Science "breast neoplasm*" OR 
rnammogra* OR "clinical 
breast exam" OR CBE) 
AND ( overdiagnos* OR 
overtreat* OR overdetect*) 
BIOS IS ("breast cancer*" OR 69 Results 4 ,, ... , I''" 
11 breast neoplasm*" OR 
mammogra* OR 
11 Clinical breast exam" OR 
CBE) AND ( overdiagnos* 
OR overtreat* OR 
overdetect*) 
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Figure 2: Flow Chart of Prostate Cancer Search and Inclusion 
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Figure 3: Flow Chart of Breast Cancer Search aud Inclusion 
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Quality Assessment 
The quality of studies was largely assessed using the U.S. Preventive Services Task force 
criteria in Table 4. 140 However, because there were a number of modeling studies included in the 
analysis, it was necessary to develop criteria with which to assess the internal validity of these 
studies (Table 5). For modeling studies which used data from previous studies, the quality of 
both the modeling process and the study whose data the model used was assessed. In addition, 
external validity was assessed using USPSTF defined criteria by examining studies for biologic 
plausibility, similarity between the population in the study and primary care patients, similarity 
of the intervention used to the screening intervention commonly used in clinical practice, and 
clinical or social environmental circumstances that could give different results than those that 
would be expected in a primary care environment. 
Table 4: Criteria for Grading the Internal Validity of Individual Studies 
Study Design Criteria 
Systematic Reviews • Comprehensiveness of sources/search strategy used 
• Standard appraisal of included studies 
• Validity of conclusions 
• Recency and relevance 
Case-Control Studies • Accurate ascertainment of cases 
• Nonbiased selection of cases/controls with exclusion criteria applied 
equally to both 
• Response rate 
• Diagnostic testing procedures applied equally to each group 
• Appropriate attention to potential confounding variables 
Randomized Controlled Trials • Initial assembly of comparable groups: 
and Cohort Studies For RCTs: adequate randomization, including concealment and whether 
potential confounders were distributed equally among groups 
For cohort studies: consideration of potential confounders with either 
restriction or measurement for adjustment in the analysis; consideration 
of inception cohorts 
• Maintenance of comparable groups (includes attrition, crossovers, 
adherence, contamination) 
• Important differential loss to follow-up or overall high loss to follow-up 
• Measurements: equal, valid, and reliable (includes masking of outcome 
assessment) 
• Clear definitions of interventions 
• All important outcomes considered 
• Analysis: adjustment for potential confounders for cohort studies, or 
intention-to-treat analysis for RCT's 
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Table 5: Criteria for Gradin2 the Internal Validitv of Overdia1mosis Modelin2 Studies 
Type of Study Criteria 
Modeling based on RCT, • Data used for modeling comes from high quality studies based on Table 3 
cohort, or service screen data criteria 
• All relevant variables should be included in the model 
• Estimates for model parameters come from quality studies (lead time, 
transition probabilities in Markov models) 
• Follow-up should be long enough to outlast the prevalence peak due to 
lead time 
• Comparison groups should be applicable and as similar to the 
intervention group as possible for service screening modeling 
• Contamination of the comparison group should be minimal 
• Authors should discuss the role oflead time and the impossibility of 
completely distinguishing it from overdiagnosis 
• A probabilistic sensitivity analysis should be performed to assess the 
effects of varying different parameters, including lead time 
Data Extraction 
Studies that were included after the initial search were reviewed in more depth to 
determine whether they fit all inclusion criteria. Data from each study was extracted into a 
standard table to allow for easy comparison with inclusion criteria (Tables 5 and 6). In addition, 
the adherence of each study to the above quality criteria was assessed during the data extraction 
process. 
Table 5: Examnle Data Extraction Table--Studv Characteristics 
Study Definition of Sample 
and Date Study Overdiagnosis Characteristics Method. Interventions Outcome 
Extracted Design and Formula (size, selection, Quality Assessmt. 
LTFU) 
Table 6: Examnle Data Extraction Table--Results 
Study and Date Length of Dropouts Results 
Extracted Follow-Up 
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Data Synthesis 
Data synthesis was performed primarily in a descriptive manner, without the use of 
quantitative methods because heterogeneity of outcomes prevented the use of this modality. By 
qualitatively examining the heterogeneity of the results, it was possible to come to some 
conclusions about overdiagnosis and overtreatment. In addition, the quality of the studies and 
some of their resulting limitations were noted. Although some of the smaller databases and 
reference lists were searched for full-text articles, publication bias is still a concern as it is with 
any systematic review. 
Results 
Prostate Cancer 
Study Selection 
Of the 38 prostate cancer articles in Table 2 that were pulled from the literature search for 
further review, I 0 articles fulfilled all selection criteria?5• 28• 30• 33-35• 38· 41 · 43 · 45• 141 • 142 See 
appendix 1 for a reasons for inclusion and exclusion of studies. If a study was borderline for 
fulfilling selection criteria, it was left in the review. Five of the included studies are models 
validated by prostate cancer incidence in the SEER database, 25• 33• 35• 41 • 43 three are models based 
on service screening programs,28· 34· 45 and two use the same Markov model validated by RCT 
data. 
Three tables follow that give a general idea of the included studies. Table 6 lists specific 
details on the characteristics of these studies, including study design, stated definition and 
expression of overdiagnosis, sample characteristics, intervention, and length of follow up. 
Because many of the modeling studies incorporated data from previous studies into their model 
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or were validated by other studies, it was necessary to include some information about these 
underlying studies in table 6 as well. Table 7 reports the results of these studies in three ways: 
as reported in the study, converted to overdiagnosed cases /1000 patients screened (if possible), 
and converted to overdiagnosed cases /1000 cases diagnosed. Lastly, table 8 includes details 
about the quality of the included studies. 
Results 
Overall, rates of overdiagnosis ranged from 8 to 99 per 1000 patients screened and 73 to 
708 per I 000 patients with screen-detected prostate cancer and depended on the age at diagnosis, 
race, Gleason score, or mean lead time estimate used in the study. It was not possible to estimate 
the rate of overdiagnosis per 1000 patients screened for 5 of the studies due to insufficient data 
reported in the studies.25• 30• 33• 35· 41 The quality of the studies was variable, but two of the studies 
validated by SEER data were fair quality, one of the service screening studies was fair quality, 
and the two studies validated by RCT data were particularly good quality. 
Of the studies based on SEER data, Etzioni et al41 and Telesca et al25 had the best overall 
study quality. Etzioni et al fit models separately for white and black patients, and found that for 
black patients, the model fit better to incidence data using a mean lead time of 7 years, whereas 
for white patients, the model fit better when it used a mean lead time of 5 years. This 
corresponded to overdiagnosis rates of288 per 1000 white screen-detected patients and 438 per 
I 000 black screen-detected patients. These rates varied slightly depending on what proportion of 
PSA's the authors assumed were diagnostic versus screening. Telesca et al actually used the 
same model as Etzioni et al, but used a likelihood model for secular trend in prostate cancer 
incidence to model it concurrently with lead time. They found that overdiagnosis rates were 
slightly less when estimated in this way: 227 per I 000 white screen-detected patients and 344 
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per 1000 black screen-detected patients. A caveat to these studies is that they do not model a 
specific screening regimen; they model the rate of PSA screening between 1988 and 1998 based 
on Medicare claims data and assume in the model that screening occurs at this baseline rate. 
Other models using SEER incidence data as validation include Etzioni et a!, 43 Davidov et 
a!,35 and Tsodikov et a1.33 Etzioni eta! found a similar overdiagnosis rate of247 per 1000 
screen-detected stage Al cancers for annual PSA screening with a cutoff of 4, but expressed 
overdiagnosis as a proportion of stage Al (low stage) cancers, which leaves out the potential for 
overdiagnosis in high stage cancers. Rates were lower for less frequent screening and when 
using age-specific PSA cutoffs. Davidov eta! found that rates for 50 to 70 year olds screened 
with PSA (cutoff not stated) every 5 years had an overdiagnosis rate of 307 per 1000 screen-
detected cases, assuming a lead time of 10 years. Rates were higher for longer sojourn times and 
were also higher for wider age ranges screened. Tsodikov eta! found overdiagnosis rates of 100 
to 500 cases depending on the age at which screening occurred. The authors in this study 
assumed that screening was a random process; they did not model the impact of a specific 
screening interval. The results are not reported in a useful format in this study; the values above 
were extrapolated from a graph of overdiagnosis versus age. 
The best quality model based on a service screening population was Ciatto et al,34 which 
found the rates of overdiagnosis to be higher. Using two biennial screening rounds ofPSA with 
a cutoff of 10, DRE and TRUS over 9 years of follow up, the authors estimated that 
overdiagnosis would occur in 399 patients per every I 000 screen-detected cases and in 17 
individuals per every 1000 patients screened. Other service screening models included Zappa et 
al45 and Hamashima et al. 28 Zappa et a! found that for patients screened with biennial PSA with 
a cutoff of 4 starting at age 60, overdiagnosis occurred in 201 patients per 1000 screen-detected 
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cases and 6 patients per I 000 patients screened, assuming a 2% increase in baseline prostate 
cancer incidence per year. Rates were higher if screening were started at age 65 and if the model 
assumed a constant baseline incidence. Follow up of the patients in the service screening study 
was only 4 years in this model. Hamashima eta! found that patients screened with one-time PSA 
with a cutoff of 2. 7 had a rate of overdiagnosis of 708 cases per I 000 screen-detected cases and 8 
per I 000 patients screened. However, this study only had a follow up of I year, thus much of the 
increased incidence detected in the study is likely prevalent cases of prostate cancer. A problem 
in all these screening studies is that they assume that all excess incidence occurs due to 
overdiagnosed cases when there are undoubtedly some cases of prostate cancer that were caught 
early by screening that would have presented clinically later. The longer the follow up in the 
study, the less of a concern this is. 
Two studies were based on a single model developed by Draisma et al,38 which validated 
the model using both population level incidence data from The Netherlands in 1991 and data 
from a randomized controlled trial that randomized over 42,000 patients to screening or no 
screening and had 6 years offollow up data available. Draisma eta! found that for annual PSA 
screening with a cutoff of3 of men 55-75, overdiagnosis rates were higher: 560 cases per I 000 
screen-detected cases and 79 cases per I 000 men screened. Rates of overdiagnosis in this study 
were lower for single screening, slightly lower for a smaller age range screened (55-67 year olds), 
and slightly lower if using a four year screening interval instead of annual screening. Parker et 
aeo used the same model to estimate overdiagnosis rates based on stage-specific detection rates 
from a prospective cohort study of untreated or minimally treated prostate cancer. 143 The authors 
estimated overdiagnosis rates in 60-64 year olds were 278 per I 000 screen-detected cases of 
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prostate cancer with a Gleason score of7. Rates of overdiagnosis were higher for lower Gleason 
scores and lower for younger age groups screened. 
Breast Cancer 
Study Selection 
Of the 51 breast cancer studies in Table 3 that were pulled from the literature search for 
further review, II articles fulfilled all selection criteria.s, 28, 83, 86, 88, 89, 91, 99, 102, 107, 112, 135 
Appendix 2 contains reasons for inclusion and exclusion of all studies. If a study was borderline 
for fulfilling selection criteria, it was left in the review. Eight of the included studies are based 
on population-based service screening programs28• 83· 88· 89· 99· 102• 107· 112 and three are based on 
RCT data. 5' 86' 91 
Three tables follow that give a general idea of the included studies. Table 9 lists specific 
details on the characteristics of these studies, including study design, stated definition and 
expression of overdiagnosis, sample characteristics, intervention, and length of follow up. This 
table also contains information about the analysis used to calculate overdiagnosis. Table 7 
reports the results of these studies in three ways: as reported in the study, converted to 
overdiagnosed cases I I 000 patients screened (if possible), and converted to overdiagnosed cases 
I 1000 cases diagnosed. Lastly, table 8 includes details about the quality of the included studies. 
Results 
Overall, rates of breast cancer overdiagnosis ranged from 4 to 14 overdiagnosed cases per 
1000 patients screened and 22 to 600 overdiagnosed cases per 1000 patients with breast cancer. 
These values varied in some studies depending on the sensitivity of mammography and whether 
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invasive and in situ cases were considered together or separately. It was not possible to estimate 
the rate of overdiagnosis per 1000 patients screened for 8 of the studies due to insufficient data 
reported in the studies. 83• 86• 89· 91 · 99• 102• 107• 112 The quality of the studies was variable, with two of 
the studies validated by SEER data were fair quality, one of the service screening studies was 
fair quality, and the two studies validated by RCT data were particularly good quality. 
Two of the studies based on service screen data, de Koning et al83 and Olsen et a!88 used 
the same basic model of chronic disease progression 144 to calculate expected incidence and 
compare this to the observed incidence in the screened cohort. This model fits a Poisson 
distribution to the data to estimate the values of parameters such as lead time, sensitivity, 
incidence of preclinical screen detectable cancers, and incidence of overdiagnosed cancers using 
predefined equations. De Koning et a! used 8 years of service screen data and found that 80 
cases of breast cancer would be overdiagnosed per 1000 screen-detected cases of breast cancer. 
Olsen et a! used 6 years of service screen data and found that 78 cases of breast cancer would be 
overdiagnosed per 1000 screen-detected cases of breast cancer at the first screen. 
Paci et a]89 also used a Poisson regression to model expected incidence based on service 
screening data, but they took a different approach to modeling the effect oflead time. The 
authors calculated the contribution oflead time to excess incidence found in the service 
screening study by assuming an exponential distribution of lead times and using a model to 
generate a separate lead time for each individually screened patient. The probabilities that these 
cases would come to clinical detection each year after screen detection were summed to generate 
the number of screen-detected cases that would have arisen clinically each year in the absence of 
screening. The authors subtracted this number from the observed number of cases to correct for 
lead time, and compared the corrected number of cases with the expected number of cases from 
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the Poisson regression model. They found that 34 overdiagnosed cases would occur per I 000 
breast cancers diagnosed. A similar, earlier model by Paci et al99 based on Florence service 
screening data found that less that 50 overdiagnosed cases would occur per I 000 breast cancers 
diagnosed. 
Zahl et al 1 02 is another model based on service screening data that uses Poisson regression 
to calculate expected age-specific incidence rates of breast cancer in the absence of screening. 
The authors compare this to the observed incidence from the service screening data to generate 
the excess incidence due to screening, which the authors assume to be all a result of 
overdiagnosis. This model does not include an attempt to distinguish lead time from 
overdiagnosis. The follow up in the model is 5 years in the Norway service screen and 15 years 
for Swedish service screen. The authors found overdiagnosis rates of351 overdiagnosed cancers 
per 1000 cases in Norway and 310 overdiagnosed cancers per 1000 cases in Sweden. Anttila et 
al 107 used similar methods for a cohort of women in Helsinki, Finland with 8.5-11.5 years of 
follow up and found that approximately 150 overdiagnosed cancers occurred for every 1000 
breast cancer cases. Peeters et al 112 also used similar methods for a screened cohort in The 
Netherlands and found that 99 overdiagnosed cases occurred per 1000 breast cancer cases 
diagnosed. Hamashima et al28 was a low quality study that found an excess incidence of 600 
cases per every 1000 screen detected cancers after only one year of follow up in a small Japanese 
screened cohort. 
The studies based on RCT data also differed from each other in methods and results. 
Gotzsche et al86 performed a systematic review of7 RCT's of breast cancer screening and 
concluded that only two of them, the Malmo tria1145 and the Canada trial, 146 were adequately 
randomized. The authors expressed overdiagnosis as the percent excess incidence in the 
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screened group as compared to the control group. After 7-9 years of follow up, the authors 
found an excess incidence of approximately 230 cases per I 000 cancers diagnosed in the two 
trials, which they assumed was all a result of overdiagnosis. Zackrisson et al91 performed a 
similar analysis with longer follow up: I 0 years of trial data and 15 years of follow up past the 
end of the trial. They found an excess incidence of just 91 cases per 1000 cancers diagnosed, 
which they assumed was all due to overdiagnosis. 
Duffy et a15 used RCT data in a Poisson regression to model the expected incidence, and 
they used the model of Day and colleagues144 (the same model used in de Koning et al and Olsen 
et al above) to estimate the values for lead time, sensitivity, and incidence of screen-detectable 
and overdiagnosed cancers. Taking these parameters into account, they found a rate of 
overdiagnosis at the first screen of 32 cases per I 000 screen-detected cancers in the Swedish 
Two County Trial and 42 cases per 1000 screen-detected cancers in the Gothenburg Trial. Thus, 
after taking lead time into account, estimates of overdiagnosis are less than in the studies above 
that did not take lead time into account in the model, even in studies with longer follow ups such 
as Zackrisson et a!. 
Discussion 
Overdiagnosis in Prostate Cancer Screening 
Thus, for prostate cancer, estimates of overdiagnosis from the highest quality studies 
noted above range from 227 to 560 overdiagnosed cases per 1000 screen-detected cases of 
prostate cancer. This does not take into account the very high rates of overdiagnosis found by 
Parker et al for patients over 65 years of age with Gleason scores of7 or less-up to 766 
overdiagnosed cases per 1 000 patients screened. Some factors associated with a higher rate of 
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overdiagnosis include black race (due to longer lead time), lower Gleason score, and wider and 
older age ranges screened. More frequent screening, i.e. a shorter screening interval, was 
associated with a slightly increased rate of overdiagnosis in some studies. In addition, using 
higher mean lead time values and assuming a constant or declining secular trend in incidence 
were associated with higher rates of overdiagnosis in these studies. The two higher quality 
studies for which overdiagnosed cases per 1000 patients screened could be estimated had 
overdiagnosis rates of 17 and 79 cases per patient screened. The PSA cutoffs used in these 
studies differed widely, with a cutoff of 10 in Ciatto et a! and a cutoff of 3 in Draisma et a!. This 
difference could lead to the lower overdiagnosis rates in the Ciatto study due to the detection of 
larger, more advanced cancers that would have both secreted more PSA and been more likely to 
present clinically. 
The studies had a great deal of heterogeneity in many baseline characteristics, including 
intervention modeled in the study. All studies modeled PSA, yet the screening interval and 
cutoff for the test varied widely between studies. Three studies did not choose a specific 
screening interval to model as the intervention; these studies estimated current PSA screening 
rates from a linkage between the SEER database and Medicare claims and thus modeled the 
current screening situation. However, when doing this, difficulties arose distinguishing between 
screening PSA's and diagnostic PSA's from the database. Some of the studies introduced 
parameters to help control for this. For example, Etzioni et a!41 incorporated a parameter "p" 
representing the proportion of all PSA -associated cases (cases of prostate cancer diagnosed 
within 3 months of a PSA test) that were screen-detected. They performed a sensitivity analysis 
using high, moderate and low values for p, and found that the difference in overdiagnosis using 
different values for "p" was less than I 0 cases of overdiagnosis per I 000 patients with screen-
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detected cancer, but tended to favor slightly increased overdiagnosis rates for low values for p. 
Other studies, including Draisma et a!, modeled multiple interventions. Four studies modeled 
some type of biennial PSA screening; one of these used a cutoff of 10, two of these used a cutoff 
of 4, and the other used a cutoff of 3. Two studies modeled screening every 5 years and two 
modeled screening every 4 years. In addition, one study modeled PSA screening using an age-
specific cutoff defined in a previous study. 147 Thus, a great deal of heterogeneity is present in 
intervention modeled that makes it difficult to analyze study results. 
In addition, the age distribution of the population of interest varied a great deal between 
the studies. Some of the age ranges modeled in these studies include all men over 50, men 50-84, 
men 55-74, men 60-74, men over age 55, men 60-84, men 30 to 95, men over age 60, and men 
over age 65. Overall, indications are that for higher age screened, the rates of corresponding 
overdiagnosis are also higher, which makes sense given the increasing risk of dying of a 
comorbid condition with increasing age. Some studies, such as Parker et a130 and Draisma et 
al,38 modeled multiple different age groups of interest and found that older patients did in general 
have higher overdiagnosis rates than younger patients. 
The overall quality of the modeling studies varied, as seen in table 8. The internal 
validity of modeling studies depends on a number of factors, including completeness of the 
model, accuracy of parameters, similarity of comparison groups, assumptions, and length of 
follow up. All modeling studies make assumptions when combining different parameters in the 
study, and some ofthese modeling studies made more assumptions than others. Length of 
follow up is an important factor for studies based on service screening cohorts that affects the 
internal validity of these studies. The longer the length of follow up, the less likely any excess 
incidence beyond the expected incidence is due to prevalent cases. 
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One of the most common assumptions made was that the distribution of lead times in a 
given population followed a given distribution, such as an exponential distribution. It is not 
possible to know with certainty what the distribution oflead times is in a given population for 
prostate cancer because the data is not there. More aggressive cancers will have short lead times 
and less aggressive cancers will have longer lead times, but we cannot whether the distribution of 
these lead times is normal, exponential, bimodal, or skewed. It is more likely that the 
distribution oflead times does not follow a defined type of distribution. Studies that do not 
assume that lead time follows a specific distribution do not take it into account at all, and thus 
the quality of their estimate is highly dependent on length offollow up. Another common 
assumption was that parameters used in the study could be generalized to one another in one 
model even though they were determined in different populations. Finally, many models assume 
that the all-cause mortality in patients with screen-detected prostate cancer is similar enough to 
that of the population as a whole to use census mortality rates when generating date of death. 
Follow up and contamination were two major quality issues in the studies based on 
service screening populations. Hamashima eta! had follow up of I year and Ciatto et a! had 
follow up of 9 years. Zappa et a! had follow up of 4 years in the screened population, but 
modeled 14 years worth of follow up. When calculating an observed to expected incidence ratio 
in these studies based on service screening data, it is important that the cohort used to estimate 
the expected incidence is both similar to the observed cohort and free of contamination by 
opportunistic screening. Zappa et a! calculated expected incidence based on age specific 
mortality rates from the Tuscany Cancer Registry in 1990-1991, a period in which they say 
screening was negligible. However, they offer no data to back up this claim. Ciatto et a! 
calculated expected incidence based on age specific mortality rates from the Tuscany Cancer 
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Registry during the period of screening (1991-1994), a period in which they say screening was 
negligible. They mention that the screened cohort actually made up 3 percent of the individuals 
in the Tuscany Cancer Registry. Thus, 3 percent of the individuals in the expected group were 
contaminated by screening, and so overdiagnosis may be slightly underestimated in this study. 
In Hamashima et a!, the expected incidence is calculated from incidence rates in 11 Japanese 
cancer registries. The authors do not mention the potential for opportunistic screening of these 
patients, thus the risk of contamination in this group is high. 
The generalizability of these studies was greater in studies validated by population level 
data such as the SEER database because they were based on a wider spectrum of individuals, but 
some internal validity is sacrificed without validating the model against a randomized controlled 
trial or controlled cohort study. Generalizability suffers when patients were excluded from 
validation studies because of exclusion criteria or a narrow age range for screening. Studies that 
modeled blacks and whites separately have better external validity to these specific populations 
than those that modeled all races together. 
Implications for Overtreatment of Prostate Cancer 
The results of these modeling studies indicate that approximately 23 to 56% of all screen-
detected prostate cancer cases will be overdiagnosed in a population-based screening program. 
Rates are higher in older patients and those with low stage disease. Overdiagnosed patients will 
be likely to undergo further diagnostic testing, including prostate biopsy, and also treatment. 
Little data exists about the proportion of overdiagnosed patients who are treated, but data does 
exist that focuses on the treatment of prostate cancer by stage and grade. It is difficult to 
estimate the likelihood of treatment of overdiagnosed cases because overdiagnosed individuals 
may have cancers of any clinical stage and grade. However, overdiagnosed cases are more 
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commonly lower risk cancers because they have longer lead times during which patients may die 
of comorbid conditions. Studies show that 76-85% of screen-detected cases are Gleason score< 
7, the patients at greatest risk for overdiagnosis. 30 It would make sense for treatment patterns to 
be more conservative in patients with low-risk cancers because it is less likely that they will die 
of their prostate cancer. However, current data suggests that this is likely not the case. 
A retrospective cohort study based on the SEER registry estimated the proportion of men 
with "lower-risk" prostate cancers who were overtreated, assuming that any treatment other than 
expectant management was overtreatment.29 They defined "lower risk" as men with Gleason 
score 2-4 cancers or men over 70 years old with Gleason score 5-7 cancers. The authors found 
that I 0 percent of 24,825 men with low risk cancers were overtreated with surgery and 45% of 
the men were overtreated with radiation therapy. This does not take into account the men who 
may have been treated unnecessarily with androgen deprivation therapy. The CaPSURE study, a 
survey of over 8,000 men with biopsy-proven prostate cancer, found that of the approximately 
5,000 men with localized disease, only 5.5 percent of them claimed watchful waiting as primary 
disease management from 1998 to 2000. 148 This proportion had actually declined from 7.5% in 
1989-1991 and 9.5% in 1992-1994. The authors defined localized disease as clinical stage T3a 
or less with no evidence oflymph node involvement or metastasis. The results of the CaP SURE 
study indicate that as the likelihood of active treatment for prostate cancer increased throughout 
the 1990s, which is the same time period during which the introduction of PSA screening 
occurred. From 1999 to 2001, the authors found that radical treatment occurred in 77.5%, 75.8%, 
and 47% oflow-, intermediate-, and high-risk patients, respectively. Thus, low risk patients 
were much more likely to receive radical treatment than patients with high-risk cancers. 
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Bill-Axelson et al149 performed a randomized controlled trial directly comparing radical 
prostatectomy and watchful waiting in 695 men under 75 years of age with a life expectancy of 
I 0 years with newly diagnosed stage Tl b, Tl, or T2 cancers. The authors found that fewer men 
died in the surgery group than in the watchful waiting group (30 vs 50; p = 0.01). However, this 
study excludes individuals at highest risk of overdiagnosis by excluding men over 65 and those 
with a life expectancy ofless than I 0 years. In addition, the authors found that men over 65 
years of age had a lower cumulative incidence of prostate cancer specific death. Parker et al30 
used data from a 15 year cohort study of patients with conservatively treated prostate cancer143 in 
a model to estimate the effect of radical treatment on survival. They included in their model an 
estimate of overdiagnosis in these patients based on the model used by Draisma et al as well as 
the hazard ratio from Biii-Axelson et al. They found that survival benefit was greatest in patients 
with high grade disease, which conflicts with the current patterns of care from the CaPSURE 
study. Thus patients with lower grade disease seem to be at high risk for invasive treatment with 
little survival benefit, placing them at high risk of overtreatment. 
Significant side effects can occur as the result of treatment for prostate cancer, including 
impotence, urinary incontinence, and pain. These problems occur more often in older patients, 
thus many overdiagnosed patients are at higher risk of treatment-related adverse effects. The 
Prostate Cancer Outcomes Study150 found that older men were more likely to have high levels of 
incontinence after surgery(l4% of75-79 year olds as compared to 0.7-4% of younger men). In 
addition, men over the age of 60 were more likely to have problems with impotence after surgery 
than younger men (78-85% vs. 61 %). Similar problems can occur after external beam 
radiotherapy and brachytherapy. 
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Active surveillance is one treatment option for patients with low risk cancers that could 
help limit the extent of overtreatment and adverse effects. Active surveillance is an expectant 
management protocol with frequent monitoring of PSA doubling time, velocity, or amplitude 
and symptomatology with the option of curative therapy should progression occur. Some 
algorithms include repeat biopsies of the prostate to monitor progression. Active surveillance is 
inherently a more proactive approach than watchful waiting because patients are monitored so 
closely with biochemical and clinical parameters. An example of an active surveillance protocol, 
developed by Choo eta!, 151 stated the criteria for progression as a PSA doubling time< 2 years 
based on 3 separate measurements over 6 months, a final PSA > 8 or a Gleason score > 7 on 
repeat biopsy of the prostate at 12-18 months. In addition, patients were considered to progress 
if they had an increase of more than double of the maximum perpendicular diameters of the 
lesion, local progression requiring TURP, ureteric obstruction, or evidence of metastases. Active 
surveillance protocols are one way in which treatment can be tailored to the clinical situation in 
individual patients to avoid overtreatment. 
Thus according to current estimates, up to 56% of prostate cancers seem to be 
overdiagnosed, with higher rates of overdiagnosis in older patients and those with low stage 
disease, the same patients who seem to be at greatest risk for overtreatment according to the 
results of the above studies. Thus the risk of overdiagnosis and overtreatment of screen-detected 
prostate cancer are high. In addition, the risk of side effects from treatment is highest in older 
patients who are at greater risk of overdiagnosis due to comorbidities. 
Yet problems with study quality, including lead time distribution assumptions and other 
assumptions inherent to the modeling process, limit estimates of overdiagnosis. Even the highest 
quality studies make significant assumptions about lead time, expected incidence, and screening 
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vs. diagnostic PSA tests. Without high quality randomized controlled trial data with lengthy 
follow up, it is difficult to assess the true amount of overdiagnosis that occurs. In addition, it is 
extremely difficult to assess to what extent overtreatrnent occurs in these patients without 
following them on an individual basis for a long period of time, which would likely require 15 or 
20 years of follow up. The ongoing European Randomized Study of Screening for Prostate 
Cancer (ERSPC) and the U.S. National Cancer Institute "Prostate, Lung, Colorectal, and Ovary" 
Trial (PLCO) will eventually provide a much better estimate of the true amount of overdiagnosis. 
Until then, it is likely that prostate cancer screening with PSA leads to a substantial proportion of 
overdiagnosed cases, with our best estimates at 23 to 56% of all screen-detected cancers, with 
higher rates for older patients and low stage cancers. Active surveillance is a good option for 
patients with low stage disease to avoid overtreatrnent. 
Overdiagnosis in Breast Cancer Screening 
Estimates of overdiagnosis in breast cancer screening were highly dependent on whether 
the study included a method to adjust for lead time and test sensitivity. The studies which did 
adjust for lead time5• 83• 88• 89· 135 found rates of overdiagnosis ranging from 31 cases per I 000 
cases of breast cancer to 80 cases per 1000 cases of breast cancer. One of these studies based its 
model on randomized controlled trial data and the other four based their models on service 
screening data. Studies which did not adjust for lead time86• 91 • 102• 107 found higher overdiagnosis 
rates, ranging from 91 cases per 1000 cases of breast cancer to 351 cases per 1000 cases ofbreast 
cancer. Two ofthese studies based their models on RCT data, and the other two studies based 
their models on service screening data. I excluded two studies28• 112 from the above analysis due 
to poor quality. 
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The highest quality studies, Zackrisson et al91 and Gotzsche et al, 86 were based on 
randomized controlled data and neither of these studies included a measure with which to adjust 
for lead time. Zackrisson et a! found an overdiagnosis rate of 99 per 1000 patients screened, and 
Gotzsche et a! found a higher rate of 230 per I 000 patients screened. Zackrisson eta! followed 
patients for 15 years after the end of the Malmo trial, whereas follow up in the studies analyzed 
by Gotzsche et a! ranged from 7 to 9 years. The longer follow up in the Zackrisson study may 
help eliminate some cases of breast cancer that are contributing to excess incidence due to lead 
time. However, the Zackrisson trial also assumes that no 55-69 year old women in the control 
group received mammography after the end of the trial, which certainly leads to an 
underestimation of overdiagnosis rates. The shorter follow up in the Gotzsche study is 
concerning in that some cases of breast cancer, particularly DCIS, may still be cases that were 
destined to present clinically, even after 7-9 years of follow up. The Gotzsche estimate also has 
potential for contamination in the control group that may lead to an underestimation of 
overdiagnosis rates. A random sample of 500 women in the Malmo trial control group found a 
contamination rate of 24 percent during the trial. Contamination is difficult to avoid in these 
studies due to the widespread use of mammography by the time many of the trials were 
conducted. 
Studies which incorporate methods of adjusting for lead time found lower rates of 
overdiagnosis than the above studies. Duffy et al,5 de Koning et a!,83 and Olsen et a!88 used the 
model of Day and colleagues to adjust for lead time in their estimates of overdiagnosis. Duffy et 
a! was based on two randomized controlled trials and de Koning eta! and Olsen et a! were based 
on service screening data. Rates of overdiagnosis were lower in these studies, ranging from 31 
to 80 cases per 1000 breast cancer cases. The primary faults with these studies are the multiple 
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assumptions needed in the model to adjust for lead time. Similar to many of the prostate cancer 
models, this model assumes an exponential distribution of lead times in the study population. It 
is not possible to define the distribution of lead times in the population, and assuming a specific 
distribution oflead times may lead to an underestimation of overdiagnosis if the distribution of 
lead times is more bimodal, with a high proportion of both short and long lead times. Patients 
with longer lead times would be more at risk of overdiagnosis. 
The two studies by Paci et a!89• 135 also include methods for adjusting for lead time. Yet 
these studies also assume an exponential distribution oflead times with mean lead time durations 
of3.4 years in the 2004 study and 3.7 or 4.2 years in the 2006 study, depending on the patient 
age. In addition, these studies are based on service screening populations for which the potential 
for contamination in the "prescreening" group from which the authors estimated expected 
incidence remains unclear. All studies based on service screening populations also assume that 
predicted trends in incidence can be estimated from prescreening data, when in fact external 
forces such as the increasing use of hormone replacement therapy, may have led to an increase in 
breast cancer diagnosis rates independent of screening. 
Zahl et al 102 used service screening data to estimate overdiagnosis rates without adjusting 
for lead time and found rates of 310 overdiagnosed cases per I 000 breast cancer cases in Sweden 
and 351 overdiagnosed cases per 1000 breast cancer cases in Norway. Follow up was 5 years for 
Norway and 10 years in Sweden, which may still be somewhat short in order to avoid the effect 
oflead time on excess incidence. In addition, the authors assume that there is no baseline 
increase in breast cancer incidence rates due to factors other than screening, and thus assume that 
all excess incidence is a direct result of overdiagnosis. In addition, increased reporting of breast 
cancer cases to their nationwide registry could have led to falsely elevated rates of overdiagnosis. 
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The authors do not discuss the potential for contamination and do not include DCIS in their study, 
which could both lead to an underestimation of overdiagnosis rates. Similar to the other service 
screening studies above, the multiple assumptions used in this study make it difficult to figure 
out what the results mean. 
Differences in the study characteristics within the different included studies also make it 
difficult to generalize the study results to a specific population. Different study populations and 
different interventions were used in the studies. All of the studies included some type of 
mammography screening, but screening intervals varied. Some studies included 2 view 
mammography, some included one view mammography, and others did not specify what type of 
mammography they used in the study. Many studies modeled biennial mammography, but some 
studies used annual mammography, and one study used mammography every 18 to 24 months. 
In addition, the age intervals screened differed between the studies. Screening began at age 50 in 
five studies, at age 45 in two studies, at age 40 in four studies, and at age 35 in one study. Most 
studies stopped screening women at age 69, but a few studies continued to screen women until 
age 7 4 or 79. These studies would be expected to show higher rates of overdiagnosis because of 
the higher risk of comorbid disease in elderly women. 
Generalizability of the studies is most likely better in the more population-based service 
screening studies because they patients were not excluded like they were in some of the 
randomized controlled trial data. However, the women in these studies are volunteers who are 
inherently different in unknown ways from the population as a whole. In addition, most of the 
service screening studies were conducted in fairly small countries with ethnically uniform 
populations, and thus their results may not be generalizable to more diverse populations such as 
the United States. 
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Implications for Overtreatment of Breast Cancer 
The highest quality study above86 concluded that overdiagnosis occurred in about 23% of 
all screen-detected cases of breast cancer. Other estimates of overdiagnosis are as low as 3 
percent when adjustment for lead time occurs. However, the amount of contamination in these 
studies is unknown, and increases in the baseline incidence of breast cancer by causes other than 
screening are not always accounted for. Thus, overdiagnosis is likely a significant problem for 
breast cancer screening with mammography, and even more of a problem for DCIS due to its 
longer lead time. This problem is compounded by the high proportion of women with breast 
cancer treated invasively, which places many overdiagnosed women at substantial risk for 
overtreatment. 
The primary treatment options for breast cancer include lumpectomy, lumpectomy with 
radiation, and mastectomy. Unlike prostate cancer, watchful waiting has historically not been an 
option for women with breast cancer. In 1999, over 28% of women with DCIS had mastectomy, 
64% had lumpectomy, and 33% had radiation.Z2 Thus, there is potential for a substantial amount 
of overtreatment as a result ofDCIS. Ernster eta! performed a retrospective study of over 
540,000 women who underwent mammography and found that 18 percent of screen-detected 
cancers were cases ofDCIS. 18 Although none of the included studies above specifically 
modeled the rate of overdiagnosis of DCIS alone, one study that modeled the incidence of non-
progressive and progressive DCIS using incidence data from the Swedish Two County 
randomized controlled trial and multiple service screening programs found that 37% ofDCIS 
cases detected by screening were nonprogressive. 106 The authors defined nonprogressive DCIS 
as having no propensity to progress to invasive disease during the lifetime of the host. They 
estimated that at prevalence screen 30 in every I 00,000 women screened would by diagnosed 
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with non-progressive DCIS, as compared to 572 women per 1000,000 women screened that 
would by diagnosed with a progressive DCIS or invasive cancer. This seems to indicate that 
DCIS due to screening is a minor problem in screening. One caveat to this study, however, is 
that it only included women up to age 69 years of age and thus excludes elderly women who 
have the highest rates of screen-detected DCIS. 18 
In addition, other studies have shown that DCIS, progressive or not, is unlikely to lead to 
death in women aged 70 years of age and older. One modeling study found that 65 cases of 
DCIS will be detected per every I 0,000 women aged 70 and older screened for I 0 years. 152 If all 
of these cases were treated with surgery or, only I death from invasive breast cancer would be 
averted. Thus the other 64 women would be overtreated and subject to unnecessary side effects 
of surgery such as anxiety, infection, and even death. Thus, although the detection of clinically 
relevant DCIS cases is a relatively minor phenomenon in breast cancer screening, these women 
are at low risk of death and thus high risk of overtreatment. 
Regardless of the proportion of screen-detected DCIS, it is clear that the vast majority of 
screen-detected breast cancers are treated surgically. The invasive treatment of any type of 
breast cancer, DCIS or invasive, in an overdiagnosed patient would be overtreatment. Thus, if 
we assume that 23% of screen-detected breast cancers are overdiagnosed with higher risks of 
overdiagnosis in older patients, then all of these individuals will be overtreated with surgical 
therapy and possibly radiation and will be at risk of the side effects of treatment. One option for 
decreasing the risks of overdiagnosis and overtreatment due to breast cancer screening would be 
setting a stopping point for screening at a certain age. The risks of screening, including the 
potential for overdiagnosis and overtreatment, begin to outweigh the benefits as patients progress 
into their seventies. It remains unclear whether mammography leads to a reduction in mortality 
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in women over seventy years of age, and continuing screening past age 70 in women at low risk 
of breast cancer has been found to result in a small gain in life expectancy while having low cost-
f" . 152 e ,ectlveness. 
The true percentage of overdiagnosis in mammography screening remains unclear, but 
the highest quality estimate at this time is 23 percent of detected cases.86 This study had 
relatively short follow up and substantial contamination (about 24% of the control group in one 
study), but it does not suffer from the multiple assumptions that many of the modeling studies 
based on service screen populations have. Better estimates of overdiagnosis are unlikely to be 
made in the future because of the high prevalence of mammography screening around the world. 
It is unlikely that control patients in the randomized controlled trials of breast cancer screening 
will remain free of mammography screening. Many of the trials invited the control group for 
screening at the end of the trial. This contamination makes it extremely difficult to measure the 
expected incidence in the absence of screening, even with extremely long follow up. As follow 
up increases, the likelihood of control patients being screened by mammography increases. It is 
not ethical to withhold mammography screening from control group women because RCT's have 
shown that it reduces mortality. 16 Therefore, it is unlikely that more accurate measurements of 
the prevalence of overdiagnosis in RCT' s of mammography screening will be made. 
Comparison of Screening for Prostate Cancer with Screening for Breast Cancer 
Overall, overdiagnosis seems to be a smaller problem for breast cancer screening than 
prostate cancer screening, but the rates of overdiagnosis are substantial in both diseases. Good 
randomized controlled trial data is present in breast cancer screening and is absent in prostate 
cancer screening, thus most estimates of overdiagnosis in prostate cancer screening come from 
modeling studies based on service screens and SEER database studies. The one study that was 
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based on preliminary RCT data found an overdiagnosis rate of 56% of screen-detected cases. 38 
Nearly all of the prostate cancer studies included an adjustment for lead time, assuming an 
exponential distribution oflead times, because there was no long-term follow up of high-quality 
RCT data. The breast cancer studies showed fairly dichotomous results when lead times were 
modeled based on an exponential distribution as compared to when there was no adjustment for 
lead times. Adjustment for lead times led to lower rates of overdiagnosis, from 3.1 to 8.0% of 
breast cancer cases, as compared to 9.9 to 35.1% of breast cancer cases when authors did not 
adjust for the effect oflead time. Overall results of the highest quality studies were 
overdiagnosis rates of23 to 56% of prostate cancer cases and 10 to 23% of breast cancer cases. 
Rates of overdiagnosis in prostate cancer screening tended to be higher in older patients 
and those with lower stage disease, whereas rates of overdiagnosis in breast cancer screening 
also tended to be higher in older patients. It is likely that rates of overdiagnosis are higher in 
patients with DCIS, although this is unclear because none of the studies modeled DCIS 
separately. However, in multiple studies the rates of overdiagnosis of invasive and in situ 
cancers were higher than the rates of invasive cancers alone, indicating that patients with DCIS 
are at higher risk of overdiagnosis. In addition, 
A high percentage of screen-detected cases in both conditions are treated invasively, with 
higher rates of invasive treatment occurring in breast cancer. Invasive treatment for breast 
cancer by surgery or radiation is nearly universal because there is not a treatment algorithm 
similar to watchful waiting in prostate cancer. This is most likely because DCIS makes up only 
18% of screen-detected breast cancer cases, 18 whereas low risk prostate cancer may occur in as 
many as 47% of screen-detected patients. 56 A higher proportion of patients with screen-detected 
prostate cancer thus have low risk disease that would never present clinically. Yet although the 
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risk of overdiagnosis seems to be higher for prostate cancer, the risk of overtreatment of breast 
cancer is higher because essentially all screen-detected breast cancers are treated invasively with 
surgery or radiation, whereas the study by Miller et al29 found that only 10% of localized prostate 
cancers are overtreated by surgery and 45% by radiation. 
Thus, of 1000 screen-detected cases of prostate cancer, 230 to 560 cases would be 
overdiagnosed. If 560 cases were overdiagnosed, and we assume that these are all localized 
prostate cancers, then 56 cases would be overtreated by surgery and 252 cases by radiation for a 
total of 308 overtreated cases per I 000 screen-detected cases. Of I 000 screen-detected cases of 
breast cancer, 230 would be overdiagnosed based on the highest quality estimate. All of these 
cases would be overtreated by surgery or radiation, leading to a total of 230 overtreated cases. 
Thus, despite a higher risk of overdiagnosis in prostate cancer, the use of conservative treatment 
for localized prostate cancer and the use of universally invasive treatment in breast cancer have 
led to very similar magnitudes of overtreatment in prostate cancer and breast cancer screening. 
Of course, not all overdiagnosed prostate cancer cases are localized disease, and so the estimate 
of prostate cancer overdiagnosis is overestimated. However, it is likely that the majority of 
overdiagnosed prostate cancer cases are localized due to longer lead times. Overall, about \1.1 of 
screen-detected cases in both prostate cancer and breast cancer can be expected to be overtreated. 
Many issues with study quality affect the accuracy of the overdiagnosis estimates, 
including length of follow up, assuming an exponential distribution for lead time, and 
contamination in the control groups. Long term follow up of the ERSPC and PLCO randomized 
controlled trials of prostate cancer screening will provide better estimates of the true 
overdiagnosis of prostate cancer due to screening. However, because it has been shown that 
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breast cancer screening reduces mortality, it is unlikely that better RCT estimates of 
overdiagnosis due to screening will be forthcoming. 
Conclusion 
Overdiagnosis and overtreatment represent important harms in both prostate cancer 
screening and breast cancer screening. About ~ of screen-detected cases can be expected to be 
overtreated with invasive therapy. Thus, treatment should be used judiciously in screen-detected 
patients at low risk of disease progression, particularly older patients with lower stage disease in 
prostate cancer screening and older patients with DCIS in breast cancer screening. Active 
surveillance of patients with low risk prostate cancer can be used to minimize the risks of 
overtreatment of this population. In addition, careful consideration should be given to the risks 
and benefits of surgical treatment for elderly women with DCIS, particularly those over age 70. 
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Table 6: Prostate Cancer Study Characteristics 
Study Study Design Definition and Sample Background Studies, Intervention 
Expression of Characteristics Validation, and 
Overdiagnosis Parameter Estimation 
Telesca Stochastic OD expressed as the Hypothetical cohort of I Incidence data from US SEER Based on current rates of 
200725 Simulation Model fraction of cases detected million men between 50-84 database 1973 to 2000. PSA PSA screening from the 
by PSA screening that, in yo in the US screening rates from Medicare/SEER claims 
the absence of the test, retrospective analysis of SEER database using PSA > 4. 
would not have been database, Medicare claims, and 
diagnosed within the NHIS. 153 Detection rates 
individuals' lifetimes estimated from previous 
studies. 154' 155 Mortality from 
NCHS Vital Stats. 
Hamashima Service Screening No explicit definition 2061 male volunteers over Incidence estimated from II Serum PSA using a cutoff 
200628 Model 0/E ratio calculated using: 50 enrolled from Tokyo Cancer Registries in Japan. 156 of2.7 ng/mL 
E ~I X (P/100000) X ST X SE 2/04- 1/05. Men with Sojourn time estimated as 5-15 
I = incidence previous diagnosis of yrs from 8 previous studies.37. 
P = population 
cancer or self report of 38,40-42, 157-159 It is unclear how ST =sojourn time (an estimate of 
lead time) precancerous disease were sensitivity was estimated. 
SE =sensitivity excluded. 
Expressed as the 
percentage increase in 
prostate cancer diagnosis 
in the screened population 
as compared to the 
unscreened population 
Parker Competing-risks Overdetection- the Hypothetical cohort of I Survival data from Albertsen Biennial PSA screening 
200630 hazard model. detection of cases by million men with prostate 1998 cohort study: 767 men with cutoff of 3 
Overdetection was screening that otherwise cancer aged 55 to 7 4 years with 
estimated by a would not have been clinically localized prostate 
replica of the detected cancer diagnosed between 
Draisma 2003 Expressed as the 1971 and 1984 were treated 
• Markov model proportion of screen- conservatively for up to I 0-20 
using data from the detected cases of prostate years. 1s, 143 
Albertsen 1998143 cancer that is Overdiagnosis estimates 
cohort study. overdiagnosed. validated by previous Draisma 
estimates. 
Table 6: Prostate Cancer Study Characteristics (Cont'd) 
Study Study Design Definition and Sample Background Studies, Intervention 
Expression of Characteristics Validation, and 
Overdia~nosis Parameter Estimation 
Tsodikov Mathematical Expressed as the Incidence data from Risk of death from other causes PSA; available data does 
200633 model taken proportion of prostate 350000 cases of prostate derived from the Human not distinguish b/t 
directly from cancers identified through cancer obtained from SEER Mortality Database. Age at screening and dx PSA. 
population data screening that would have database using age interval tumor onset modeled by Tests performed within 3 
(SEER database). never been detected in the 50-85 from 1973-2000. parametric distributions mos of diagnosis were 
absence of screening. (Weibull, Gamma, MVK). assumed to be diagnostic. 
Sojourn time modeled as a No cutoff specified, but 4 is 
Weibull distribution dependent likely. Assumes screening 
on age and secular trends in is a random point process 
detection. PSA screening rates in the population, thus does 
modeled from SEER database. not model a specific 
Compare observed SEER screening regimen 
incidence by year and age with 
model predicted incidence for 
validation. 
Ciatto Service Screening Detection of latent non- 6890 volunteer men aged Expected incidences were 2 biennial screening rounds 
200534 Model aggressive cancers that 60-7 4 invited in 2 cohorts taken from the Tuscany Cancer orPSA (cutoff> 10), DRE 
will never become from a random sample of registry age-specific incidence +TRUS 
clinically evident Italian National Health rates. 
Expressed as the % Service registered GP No validation. 
increase in prostate cancer offices 1991-1994. Excl: 
diagnosis in the screened Pts with disabling illnesses, 
population as compared to unlikely to attend 
the unscreened population invitation, or w/ PCA. 
Davidov Mathematical When a screening exam No population of interest All-cause Mortality from screening every 5 years 
200435 Model detects a disease that stated, but SEER database Period Life Table by the SSA with PSA (assume data 
would have otherwise used for estimation of describing mortality of US uses cutoff of 4) in 50-60 
been undetected in a incidence. males in 1997. Sojourn time yos, 50-70 yos, and 50-80 
person's lifetime because estimates of 5-15 yrs are from yos 
the individual would have 8 previous studies.38' 42' 157-162 
died of other causes prior Incidence from SEER database 
to clinical onset used in model. Sensitivity 
estimates of seem arbitrary. No 
validation. 
-
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Table 6: Prostate Cancer Studv Characteristics (Cont'd) 
Study Study Design Definition and Sample Background Studies, Intervention 
Expression of Characteristics Validation, and 
Overdia2nosis Parameter Estimation 
Draisma Markov Model Overdetection ~ screen- Hypothetical cohort of I Dutch male life table used to 19970 men in screen arm 
200338 validated by RCT detected cancers that million men aged 55 at the estimate time of death from received first screening test. 
and baseline would not have been start of screening other causes First 9766 men received 
incidence data diagnosed in the absence CI (0.19)and stage-specific DRE, TRUS, and PSA. 
of screening sensitivities (0.64, 0.91, 0.97 Biopsy ifDRE or TRUS 
Expressed overdiagnosis for localized, regional, and abnormal or for PSA > 4. 
as: distant stages) estimated by the I 0204 men in first round 
1. the relative increase, model to fit ERSPC results and all 3545 who had 
caused by screening, of Validated in 3 ways second test received PSA. 
the number of men with a I. ERSPC Rotterdam: 163 Sextant biopsy of these 
cancer diagnosed during 42376 men aged 55-74 in men for PSA > 3. 
their lifetime Rotterdam pop. registry who 
2. the fraction of were invited to participate and Modeled single screening 
irrelevant cancers of all accepted. at 55,60,65,70,75; annual 
detected cancers These men were randomly screening at 55-67 and 55-
assigned to control or 7 5, and q4 year screening at 
screening arms (21166 control, 55-67 and 55-75. 
21210 screen). 6 years of 
follow up in this study. 
2. Baseline incidence of 
prostate cancer in The 
Netherlands in 1991 
(prescreening) 
3. Baseline stage distribution 
of clinically diagnosed cancers 
in the Rotterdam Cancer 
Registry for 1992 and 1993 
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Table 6: Prostate Cancer Studv Characteristics {Cont'd) 
Study Study Design Definition and Sample Background Studies, Intervention 
Expression of Characteristics Validation, and 
Overdiagnosis Parameter Estimation 
Etzioni Stochastic Overdiagnosis = the Hypothetical cohort of2 Age distribution and age- Modeled 1988-1998 I 
200241 
I 
Simulation detection, through million men aged 60-84 in specific mortality rates from amount of screening using 
Model screening, of disease that 1988 census data. PSA with a cutoff of 4 
would never have been PSA testing rates and cancer 
diagnosed in the absence detection rates for 1988-1998 
of such screening from US SEER and Medicare 
Expressed as the fraction claims Databases for men 60-
of cases detected by PSA 84. 164' 165 Lead times of3, 5, 
screening that, in the and 7 years were used from 
absence of the test, would previous studies.42' 158' 159 To 
not have been diagnosed estimate the secular trend, they 
within the individuals' used trends in TURP detected 
lifetimes (the probability cancers up to 1988 
of dying of other causes extrapolated out to 1998 in 
during the lead time) absence ofPSA. 10 years of 
follow up in this data. 
Not much validation in this 
model other than SEER 
incidence. 
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Table 6: Prostate Cancer Stndv Characteristics (Cont'd) 
Study Study Design Definition and Sample Background Studies, Intervention 
Expression of Characteristics Validation, and 
Overdiagnosis Parameter Estimation 
Etzioni Markov Model Overdiagnosis - cases of Hypothetical cohort of All cause mortality, 5 Interventions Modeled, 
199943 prostate cancer detected 200000 men 30 to 95 asymptomatic incidence, stage including annual PSA 
by screening that would transition rates from previous screening with a cutoff of 
have never been Markov Model. 166 Death from 4, biennial PSA screening 
diagnosed in the absence other causes from US life with a cutoff of 4, q5 year 
of screening tables from NCHS. Data from PSA screening with a 
Expressed as: the number Pre-P SA era used for cutoff of 4, annual PSA 
of patients with screen- probability of clinical screening with an age-
detected prostate cancer presentation and stage specific cutoff, and biennial 
without clinical distribution. 167 PSA PSA spreening with an age-
presentation before death I distribution from previous specific cutoff 
all patients with stage AI study. 147 PCA death rates 
disease without screening are from 
SEER 1973-1987 data. 
Validation: Modeled age-
specific incidence and survival 
compared to SEER 1984-1988. 
Modeled sojourn time of 10-11 
yrs compared to known 
estimates. 162 Stage distribution 
validated against pvs study. 154 
Detection rate and positive 
predictive value compared to 
h d 155 s ... pvs co ort stu y. ensttlvtty 
and specificity validated 
. . h I~ 
agamst retrospective co ort. 
Zappa Service Screen Overdiagnosis - 2 Hypothetical cohorts of Model Used detection rates and biennial PSA for 5 
199845 Model using Expressed as the 10,000 men each aged 60 sensitivities from Florence consecutive rounds 
Monte-Carlo proportional excess of or 65 at screen initiation Pilot Studies: 
sampling for cancers detected by 2740 males living in Florence 
simulation screening with respect to aged 60-74 years from 1992 to 
that expected in its 1995 168 screened twice over 4 
absence years of follow up 
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Table 7: Prostate Cancer Studv Results 
Study Reported Results Overdiagnosed Cases I 1000 Pts Overdiagnosed Cases I 1000 
Screened Cases Detected 
Telesca Overdiagnosis in whites- 22.7% Cannot calculate without more Whites ~ 227 /I 000 cases 
200725 Overdiagnosis in blacks~ 34.4% information, such as the actual number of Blacks ~ 344 I 1000 cases 
overdiagnosed cases in whites and blacks 
Hamashima 0/E ratio~ 3.43 (p ~ 0.0022) forST~ 10, SE ~ 70% 17 excess cancers I 2061 men screened~ 17 excess cancers I 24 detected cancers -
200628 0/E ratio~ 5.36 ~ 16.07 when ST ~ 5 and SE ~ 30- 8.2 overdiagnosed cases I 1000 patients 708 overdiagnosed cases I 1000 cases 
90%. screened detected 
0/E ratio > I for all ST ~ 15 yr analyses 
Parker Overdetection rates ranged widely depending on age Used simulated cohort of I million men Age Gleason Overdiagnosis Rate 
200630 group and Gleason score Impossible to calculate this rate without 55-59 <7 3 71 I 1000 cases 
55-59 yo's with Gleason> 7 had 7.3% OD detection rates within each cohort group ~7 161 I 1000 cases 
70-74 yo's with Gleason< 7 had 76.6% OD for biennial screening (not available) >7 73 I I 000 cases 
Sensitivity ranges were extremely wide for all 60-64 <7 541 I 1000 cases 
estimates ~7 278 I 1000 cases 
>7 121 I 1000 cases 
65-69 <7 669 I I 000 cases 
~7 435 /I 000 cases 
>7 258 /1000 cases 
70-74 <7 7 66 I 1000 cases 
~7 575/1000 cases 
>7 369 /I 000 cases 
Tsodikov % overdiagnosis ranges between 58% and 30% Impossible to calculate this rate without Estimated based on graph: 
200633 depending on the age of the patient; overall risk of detection rates within each age cohort Age Overdiagnosis Rate 
overdiagnosis for men entering the age risk zone for 55 I 00 I 1000 cases 
prostate cancer= 25% 60 I SO I 1000 cases 
Figure 7: overdiagnosis increases from ~ 10% at the 65 250 /1000 cases 
age of 55 to -70% at the age of 95 70 300 /1000 cases 
75 400 I 1000 cases 
80 500 I 1000 cases 
Ciatto SIR~ 1.66% for screened individuals, and 1.26 for all Over 9 years flu: Over 9 years JJu: 
200534 individuals (possible selection bias/external validity Observed~ Expected I# screened~ 45.5 I Observed~ expected I observed~ 45.5 I 
issue here). This is over 9 years of follow-up. After 5 2664 ~ 17 cases I I 000 pts screened 114 ~ 399 OD cases /1000 cases 
years, SIR~ 1.17 in invited, screened pts and 1.1 in all 
patients. After 5 years flu: After 5 years f/u 
(38 ~ 32.4) /2664 = 2 cases /1000 pts (38 ~ 32.4) /38 = 147 OD cases /1000 
screened (fewer pts likely screened 5 yrs cases 
after initiation)_ ___ 
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Table 7: Prostate Cancer Studv Results (Cont'd) 
Study Reported Results Overdiagnosed Cases I 1000 Pts Overdiagnosed Cases I 1000 
Screened Cases Detected 
Davidov Overall range~ 8.48% to 53.6% depending on lead Cannot be calculated from this model For Sn- 0.7 
200435 time, sensitivity, and exam schedule. For 50- 75 yo For50-75 q5yrprotocol, IOyrMST, Sn~ 
men with 10 yr lead time and 0.9 sensitivity, OD ~ 0.9, OD ~ 300 11000 cases, or 330 I 1000 
30% (33% if screened annually) cases if annual screening occurs 
Protocol MST ODRate 
MST = mean sojourn time 50-60 q5 5yr 85 I 1000 cases 
50-60 q5 7.5 yr 144 I I 000 cases 
50-60 q5 10 yr 206 I 1000 cases 
50-60 q5 12.5 yr 26211000 cases 
50-60 q5 15 yr 31411000 cases 
50-70 q5 5 yr 151 I 1000 cases 
50-70q5 7.5yr 234 I I 000 cases 
50-70 q5 10 yr 307 11000 cases 
50-70 q5 12.5 yr 37111000 cases 
50-70 q5 15 yr 426 I 1000 cases 
50-80 q5 5yr 233 11000 cases 
50-80 q5 7.5 yr 330 11000 cases 
50-80 q5 10 yr 410 I 1000 cases 
50-80 q5 12.5 yr 47411000 cases 
50-80 q5 15 yr 527 I 1000 cases 
Draisma Single screening at: Single Screening at: Single Screening at: 
200338 55 ~ 4 irrelevant cases I I 000 men screened~ 27% of 55 ~ 4 OD cases I I 000 men screened 55 ~ 270 OD cases I 1000 cases 
detection; 6% increased lifetime risk ofPCA dx 60 ~ 12 OD cases 11000 men screened 60 ~ 380 OD cases 11000 cases 
60 ~ 1211000 ~ 38%, 18% 65 ~ 24 OD cases I I 000 men screened 65 ~ 4 70 OD cases I 1000 cases 
65 ~ 2411000 ~ 47%; 38% 70 ~ 34 OD cases 11000 men screened 70 ~ 530 OD cases I 1000 cases 
70 ~ 3411000 ~53%; 54% 75 ~ 30 OD cases 11000 men screened 75 ~ 560 OD cases 11000 cases 
75 ~ 3011000 ~56%; 47% 
Annual screening from 55-67~5lirrelevant cancers I Annual Screening: Annual Screening: 
I OOOmen screened ~ 50% of detection; 80% increased 55-67 ~ 51 OD cases II 000 men screened 55-67 ~ 500 OD cases 11000 cases 
lifetime risk 55-75 ~ 79 OD cases 11000 men screened 55-75 ~ 560 OD cases 11000 cases 
Annual screening from age 55 to 75 ~ 79/1000 ~56%; 
124% Screening every 4 years: Screening every 4 years: 
4yr screening from 55-67 ~ 41/1000 ~ 48%; 65% 55-67 ~ 41 OD cases 11000 men screened 55-67 ~ 480 OD cases 11000 cases 
4yr screening from 55-75 ~ 6611000 ~54%; 105% 55-75 ~ 66 OD cases 11000 men screened 55-75 ~ 540 OD cases 11000 cases 
·-
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Table 7: Prostate Cancer Studv Results (Cont'd) 
Study Reported Results Overdiagnosed Cases /1000 Pts Overdiagnosed Cases /1000 
Screened Cases Detected 
Etzioni Overall rates of overdiagnosis - 29% for whites and Cohort of 2 million screened-detection Assuming High "p" value (conservative 
200241 44% for blacks (best-fitting lead time for blacks was 7 rates different depending on the pt age, estimate ofOD) 
years, for whites it was 5 years). Therefore 29% and year of screening, and race LT OD Rate (W,B) 
44% of screen-detected cases would be overdiagnosed Cannot be calculated without explicit 3 173.8 I 1000,200.9 I 1000 cases 
in whites and blacks, respectively. numbers of overdiagnosed cases projected 5 285.9 I 1000, 323.1 I 1000 cases 
For lead time of 5 years, OD ~ 28.8% for whites and to occur in each race cohort per 2 million 7 392.4 I 1000, 436.6 I 1000 cases 
32.6% for blacks screened Best fitting lead times in bold 
For lead time of? years, OD ~ 39.5% for whites and 
43.8% for blacks 
Etzioni Annual PSA > 4-24.7% of stage Al cancers were OD Rate X 80,000 stage Al cancers I Annual PSA>4 
199943 overdiagnosed 200000 persons screened x 1000 ~ rate I -247 OD cases I 1000 stage Al cases 
Biannual PSA > 4 ~ 23.1% overdiagnosed 1 000 pts screened Biannual PSA>4 
Annual age specific ~ 16.8% overdiagnosed -231 OD cases I 1000 cases 
Biannual age specific= 15.4% overdiagnosed Annual PSA > 4 ~ 98.8 OD cases I 1000 Annual age-specific PSA cutoffs 
5-year PSA > 4 ~ 20.5% overdiagnosed patients screened -168 OD cases I 1000 cases 
Biannual PSA > 4 ~ 92.4 OD cases I 1000 Biannual age-specific PSA cutoffs 
pts screened -154 OD cases I 1000 cases 
Annual age specific~ 67.2 OD cases I q5 yrPSA>4 
1000 pts screened -205 OD cases I 1000 cases 
Biannual age specific~ 61.6 OD cases I 
1000 pts screened 
5-year PSA > 4 ~ 82 OD cases I 1000 pts 
screened 
Zappa For Constant incidence, OD- 51% for age 60; 93% Assumption-! 00% attendance for I 0,000 (Expected cancers with screen - expected 
199845 for age 65 men screened by biennial PSA x 5 rounds cancers w/o screen) I expected cancers 
If 2% yearly increment in incidence, OD ~ 25% for (Expected cancers with screen - expected with screen x 1000 ~ OD rate 
age 60; 65% for age 65 cancers w/o screen) I 10,000 screened x Baseline Inc. Age OD Rate 
1000 ~ OD rate Constant 60 336 I 1000 cases 
Baseline Inc. Age OD Rate Constant 65 483 I 1000 cases 
Constant 60 9. 7 I 1000 screened 2% Incr./yr 60 20 I I 1000 cases 
Constant 65 2 7. 7 I 1000 screened 2% Incr./yr 65 389 I 1000 cases 
2% Incr./yr 60 5.8 I 1000 screened 
2% Incr./yr 65 22.3 I 1000 screened 
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Table 8: Qualitv of Included Prostate Cancer Studies 
Quality of Study Similarity of 
Study and on Which Model Completeness of Comparison Questionable Length of Generalizability 
Overall Based or Model (overall Groups and Assumptions Made Follow up 
Quality Validated By completeness, Potential for by the Model 
sensitivity analyses) Contamination 
Zappa 1998'" Fair. Service screen. Fair. Includes Fair. Authors state Assumes either constant Fair. 14 years is a Fair. Population 
Only had 4 years of measures of detection that screening was incidence or 2% increase long enough period based and 
Quality: Fair follow up. rate and sensitivity, negligible in 1990- in incidence per year. to most likely cover biologically 
I 
but not competing 1991, but offer no data Assumes detection rates most lead times. plausible, but only 
causes of death. to support this at all incidence screens based on -3000 pts. ' 
conclusion. are the same as at the 
second screen. 
Etzioni 1999'" Fair. Good. Includes No comparison group Big assumption is that Good. Patients Fair. Population-
Used Cowen 1994 measures of natural necessary for this all of the parameters that modeled until age based and 
Quality: Fair Markov of prostate history, clinical model. they include in the 95 or death. biologically 
cancer progression. presentation, PSA model were calculated plausible, but only 
Incidence validated by growth curves, from similar enough models white men. 
comparing model age- screening strategies, populations to fit 
specific incidence to and survival. together properly. Also 
SEER 1984-1988. No Performed multiple assume no overdiagnosis 
validation by sensitivity analyses to in stage B, C, or D 
comparison to address some of their cancers. Multiple other 
prospective study. assumptions. assumptions about the 
values of specific 
parameters in the model. 
Etzioni 2002 Fair. Model primarily Fair. Sensitivity No comparison group Big assumption is that Good. Patients Good. Population 
used parameters from analyses varying lead for this model. the lead time parameters modeled until death. based, biologically 
Quality: Fair SEER and census times, p (the are generalizable enough Incidence data only plausible, models 
data. Lead time was proportion ofPSA- to others to be used available for I 0 white and black 
estimated at 3-7 years associated cases together. Assume that years, though. men separately. 
from 3 previous whose PSA was lead times were 3,5,or 7 
studies noted above (I screening, not years with gamma 
nested case control, I diagnostic), and distributions. Assumes 
retrospective cohort) secular trend help that all PSA tests within 
Model fit to SEER address assumptions. 3 months of dx were 
incidence data from PSA sensitivity not screening. Assumptions 
1988 to 1998. addressed in the about detection rates and 
model. secular trend. 
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Table 8: Quality of Included Prostate Cancer Studies (Cont'd) 
Quality of Study Similarity of 
Study and on Which Model Completeness of Comparison Questionable Length of Generalizability 
Overall Based or Model (overall Groups and Assumptions Made Follow up 
Quality Validated By completeness, Potential for by the Model 
sensitivity analyses) Contamination 
Draisma Good. Model Good. Model Fair. Model estimated Assumes lead time All patients Fair. Heavily 
200338 validated by data from parameters included contamination of 20 occurs in W eibull modeled until death. reliant on 
high-quality ERSPC cumulative incidence, tests I 1000 man- distribution. Assumes ERSPC Rotterdam population of 
Quality: Good Rotterdam RCT. transition probabilities years. Included a that the multiple had follow-up of Rotterdam ERSPC 
Model also validated and dwelling times for parameter in model to interventions used in the only 6 years, and the 1991 
by prescreening various stages and correct for this. ERSPC Rotterdam are though. population in The 
incidence of prostate grades, W eibull similar enough that Netherlands. Only 
cancer in The distributions, and test results are meaningful. 50% of registry 
Netherlands and stage sensitivities. Includes Assumes that all cause volunteered to 
distribution at 3 alternative models mortality in patients with participate in 
baseline. (one of which assumes screen-detected prostate Rotterdam study; 
lead time=exponential cancer is similar to the these volunteers are 
distribution) population as a whole. different from the 
rest of the 
population. 
Exclusion criteria 
not overly strict. 
Davidov Poor. Study uses Fair. Includes No comparison group Assumes sojourn time All patients Fair. Population-
200435 SEER data 1993-1997 sensitivity and sojourn necessary in this follows an exponential modeled until death. based from the 
for incidence. No time data. Does not model. distribution. Assume Only 5 years of SEER database, but 
Quality: Poor validation of model include any estimation sensitivities equal 0.3, incidence data used lack of validation 
performed of secular trend of 0.7, or 0.9. Assume from SEER compromises this as 
incidence increase or mortality of patients with database. well. 
PSA testing rates. prostate cancer is 
Sensitivity analyses identical to that of US 
for different mean lead males in 1997. 
times, screening 
schedules, and 
sensitivities. 
Mathematical design 
is difficult to 
understand. 
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Table 8: Oualitv of Included Prostate Cancer Studies (Cont'd) 
Quality of Study Similarity of 
Study and on Which Model Completeness of Comparison Questionable Length of Generalizability 
Overall Based or Model (overall Groups and Assumptions Made Follow up 
Quality Validated By completeness, Potential for by the Model 
sensitivity analyses) Contamination 
Ciatto 2005" Fair. Based on 2 Fair to poor. Does not Fair to poor. Assumes that all excess 9 years (subjects Poor. Patients 
service screen include death rates due Voluuteers are likely incidence is a result of linked with regional volunteered for 
Quality: Fair populations in to other comorbidities different from overdiagnosis; does not Tuscany Tumor screening. Florence 
Florence between or secular trends in population in Tuscany take into account the Registry and population may not 
1991 and 1994 (-7000 incidence. No Cancer Registry. possibility that some Regional Mortality be generalizable to 
men). sensitivity analyses Screened cohort is part could be earlier Registry) more diverse 
performed. of the reference diagnosis of cancers that populations. Age 
population (3%). would have presented range only 60-74. 
Authors state that clinically. Assumes that Pts with disabling 
opportunistic 9 years of follow up is illnesses and "those 
screening by PSA was long enough to uulikely to attend 
almost absent in the overcome most of the invitation" 
district when the pilots lead times for screen- excluded. 
were carried out (no detected cancer cases. 
data to back this up). 
Tsodikov Fair. Model fit to Fair. Model takes No comparison group Model assumes I 00% All patients Fair. Validation by 
200633 incidence data from many factors into used for this model. sensitive PSA test. modeled until death. population level 
SEER database 1973- account, including Assumes age at tumor 28 years of data, but not 
Quality: Fair 2000. lead time, onset is a parametric incidence data used. epidemiologic 
SEER/Medicare comorbidities, age at distribution (W eibull, studies. 
linkage used to presentation, PSA MVK, or Garmna). 
estimate PSA testing screening frequencies Assumes sojourn time 
rates. Mean sojourn and detection rates. follows a Weibull 
time from published Sensitivity analyses distribution. Assumes 
estimates. No performed for all tests performed 
validation by different age of onset within 3 months of 
epidemiologic studies. distributions. diagnosis were 
Mathematical model is diagnostic. 
difficult to understand 
----
. 
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Table 8: Oualitv of Included Prostate Cancer Studies (Cont'd) 
Quality of Study Similarity of 
Study and on Which Model Completeness of Comparison Questionable Length of Generalizability 
Overall Based or Model (overall Groups and Assumptions Made Follow up 
Quality Validated By completeness, Potential for by the Model 
sensitivity analyses) Contamination 
Parker 2006·" Fair. Model based on Good. See Draisma Fair. See Draisma See Draisma 2003. For All patients Fair. See Draisma 
survival data from 2003. 2003. this study's purposes, the modeled until death. 2003. 
Quality: Good retrospective cohort authors assumed biennial In addition, survival ' 
study. 143 Draisma screening with I 00 data used had 
2003 model used to percent attendance. exclusion criteria 
estimate excluding patients 
overdiagnosis. with metastases, 
survival less than 6 
mos., and cancers 
Hamashima Poor. Based on Fair. Does not include Poor. Not clear how Assumes that all excess Only I year of Fair to poor. 
200628 service screen parameter that similar the volunteers incidence is a result of follow up Patients are 
population in Japan estimates comorbid for screening are to overdiagnosis; does not volunteers in Tokyo 
Quality: Poor from 2004 to 2005. death rates. Does the reference take into account the who were almost all 
perform sensitivity population from ll possibility that some (>70%) 55-70. 
analysis for lead time, Japanese cancer could be earlier Exclusion of pts 
but not for sensitivity. registries. Potential diagnosis of cancers that with self reported 
Sensitivity estimation for contamination is would have presented precancerous 
is arbitrary. high because authors clinically. Authors disease may remove 
did not assess for admit that follow up is patients with 
previous PSA insufficient to correctly comorbidities. 
• 
screening . take lead time into Relatively small 
account. overall numbers of 
patients. 
Telesca 2007" Fair. Fit to Fair. Included many Good. Assumed no Assumes that lead time All patients Fair. Population-
population-based parameters in the PSA screening in fits a Gamma modeled until death. based data. Would 
Quality: Fair SEER registry 1973- model including PSA 1973-1987. distribution. Assumed Fit to 27 years of be more helpful if 
2000. PSA screening screening frequency, no PSA screening 1973- incidence data. validated by 
frequencies, cancer detection rates, and 1987. epidemiologic 
detection rates, and age-specific mortality. studies. Modeled 
age-specific mortality Lead time and secular overdiagnosis for 
rates from the CDC's trend were modeled blacks and whites 
NCHS. No validation concurrently. No separately. 
noted. sensitivity analyses. 
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Table 9: Breast Cancer Study Characteristics 
Study Study Design Definition and Sample Characteristics Validation, Analysis, and Intervention 
Expression of Parameter Estimation 
Overdiagnosis 
Duffy Markov Model fit Overdiagnosis - the Swedish Two-County: 77,080 Observed incidence from RCT S2C-single-view 
2005 5 to incidence data diagnosis of cancer as a result women 40-7 4 yo randomized data mammography 
from 2 RCT's, the of screening, usually to invitation to screening and For expected incidence, every 2yrs for 40-49 
Swedish 2 County histologically confmed, that 55,985 randomized to no fit Poisson distributions to the 2 yo and every 33mos 
Trial and the would not have arisen invitation to screening between studies to estimate incidence of for 50-74 yos 
Gothenburg Trial clinically during the lifetime 1977 and 1984. preclinical but screen detectable GT-2V 
(Day 1984 Model) of the host had screening not Gothenburg: 21,650 women progressive cancers, incidence of mammography at 
taken place 39-59 yo randomized to overdiagnosed cancers, lead first screening with 
Expressed as the % of screen- invitation to screening and time, and sensitivity using the subsequent views 
detected breast cancer cases 29,961 randomized to no model of Day and colleagues144 dependent on breast 
that were overdiagnosed invitation between 1982-1989. density. Interval 
ql8 mas 
Hamashima Service Screening No explicit definition 1725 female volunteers over 40 Incidence estimated from II 2V mammography, 
200628 Model Expressed as the percentage enrolled from Tokyo 2/04- Cancer Registries in Japan. 156 US, and physical 
increase in cancer diagnosis 1/05 Sojourn time (4-5 years) and exam 
in the screened population vs. sensitivity (70-80%) estimated 
unscreened population fr . d. !69-172 om prevwus stu 1es. 
de Koning Markov Model fit Overdiagnosis - the detection Nijmegen Service Screen~:~u Observed incidence data from Biennial 
200683 to Dutch service of breast cancers by screening Women 50-69 invited to service screen source of data. mammography 
screening that would otherwise never screening from 1990 to 1997, For expected incidence, screening 
incidence data and have been clinically then in 1999 women 70-74 fit Poisson distributions to the 2 (intervention is not ! 
also validated by diagnosed but are now treated invited. The number of women studies to estimate incidence of described in detail) 
HIP trial data Expressed as the percent of screened is unclear. preclinical but screen detectable 
(Day 1984 Model) total breast cancer incidence progressive cancers, incidence of 
that is overdiagnosed OD cancers, lead time, and 
sensitivity using the model of 
Day and colleagues144 
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Table 9: Breast Cancer Study Characteristics (Cont'd) ! 
I 
Study Study Design Definition and Sample Characteristics Validation, Analysis, and Intervention 
Expression of Parameter Estimation 
Overdiagnosis 
Gotzsche Systematic Review Overdiagnosis ~ the detection Based their estimate of Calculated relative risk of Malmo 1976: 
200686 of 7 breast cancer of breast cancers by screening overdiagnosis on 2 trials they overdiagnosis by dividing 2V mammography 
RCT's (Canada that would otherwise never judged to be adequately incidence in screened patients by in l-2nd screening 
1980, Edinburgh have been clinically randomized incidence in unscreened patients rounds, IV or 2V 
1978, Goteborg diagnosed Malmo 1976: later every 18-24 
1982, Malmo 42,484 women aged 45-69 mos. (5-6 screens) 
1976, NY 1963, Expressed as the percentage years randomized by birth year 
Stockholm 1981, increase in breast cancer cohort (21,242 screened, Canada 1980: 
Two County 1977) diagnosis in the screened 21,240 control) Annual2V 
population as compared to the Canada 1980: mammography ( 4-5 
unscreened population 89,931 women aged 40-59 screens) 
randomized individually after 
accepting invitation 
Olsen Markov Model fit Overdiagnosis ~ the 35,123 women aged 50-69 Observed incidence from the Biennial 
200688 to incidence data diagnosis of breast cancers years beginning in 1991 Denmark service screen data. mammography 
from Copenhagen that without screening would screened at least once. For expected incidence, screening 
service screening not have emerged clinically fit Poisson distributions to the 2 
program in the woman's lifetime studies to estimate incidence of 
(Day 1984 Model) preclinical but screen detectable 
Expressed as % of screen- progressive cancers, incidence of 
detected cancers at 1st screen, overdiagnosed cancers, lead 
subsequent screens, and% of time, and sensitivity using the 
all cancers diagnosed model of Day and colleagues'" 
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Table 9: Breast Cancer Studv Characteristics (Cont'd) 
Study Study Design Definition and Sample Characteristics Validation, Analysis, and Intervention 
Expression of Parameter Estimation 
Overdiagnosis 
Paci2006'" Service screening Overdiagnosis = detection at 13,519 prescreening and Observed incidence from the Unclear 
model "corrected screening of breast cancers 13,999 screen-detected breast service screening data. 
for lead time" that would not have been cancers diagnosed b/t 1986- Expected incidence modeled 
diagnosed in the absence of 200 I in women 40-79 yo in 6 with 2 step Poisson regression 
screening over a subject's cities in North/Central Italy. analysis based on prescreening 
lifetime age-, calendar time-, and area-
specific incidence rates. 
Expressed as the percentage Correction for lead time 
increase in breast cancer performed by assuming an 
incidence in the screened exponential distribution for lead 
population as compared to the time and calculating the 
expected incidence probability that each case would 
have been identified clinically 
each year after detection. 
Summing these probabilities ~ 
the # of screen-detected cases 
that would have arisen clinically 
each year in the absence of 
screening. Overdiagnosis thus is 
the ratio of actual screen detected 
cases to screen-detected cases 
that would have arisen clinically. 
MST's estimated from previous 
literature as 3. 7 and 4.2 years for 
women 50-59 and 60-74 yo 
Zackrisson RCT Overdiagnosis - the detection 42,283 women born in 1908- Calculate relative risk by mammography q 18-
200691 of cases that would never 1932 (45-69 yo) randomized to dividing incidence in screened 24 mos (see Malmo 
have come to clinical invitation to screening or group by incidence in unscreened trial) 
attention without screening control in 1976. 21,088 invited group 
Expressed as the % excess and 21,195 controls. Birth year 
cumulative incidence in the cohorts randomized separately. 
screened group as compared Screening was offered to 45-54 
to the control group yos at end of randomization, 
but not to 55-69 yos. 
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Table 9: Breast Cancer Study Characteristics (Cont'd) 
Study Study Design Definition and Sample Characteristics Validation, Analysis, and Intervention 
Expression of Parameter Estimation 
Overdiagnosis 
Paci 2004'" Service Screening Overdiagnosis - the detection 60,000 women aged 50-69 in Correct for lead time by 2V mammography 
Model with by screening of lesions that Florence invited for screening calculating the probability that a every 2 yrs from 
correction for lead would not have arisen in the from 1990- 1999. 60% screen-detected case would have 1990-1999 
time hosts' lifetimes compliance (36,000 women surfaced clinically after the end 
screened) of the study period, assuming a 
Expressed as % of detected mean sojourn time of 3.42 years 
cancers overdiagnosed and an exponential distribution 
of sojourn times. The sum of 
these probabilities was 
subtracted from the observed 
number of cases to correct for 
lead time. Expected # of cases 
determined by applying age 
specific incidence rates from 
1985-1989 to the age distribution 
of the study population. 
Zahl Service Screening Overdiagnosis - detection by Norway Service Screen: Poisson regression used to biennial 
2004102 Model screening oflow malignancy 165,000 women from4 estimate % change in age- mannnography 
lesions that otherwise would Norwegian counties invited to specific incidence rates after 
not be detected in a patient's screening every 2 yrs starting introduction of screening. 
lifetime in 1996-2001 (75% Authors exclude DCIS in 
attendance~ 120,000 screens) analysis. 
Expressed as the percentage Sweden Service Screen: 
increase in breast cancer 900,000 women 50-69 invited 
diagnosis in the screened to screening at least once 
population as compared to the screened from 1986-1996 (75% 
unscreened population attendance~ 675,000 screens) 
Anttila Service Screening No explicit definition of -47,650 Helsinki women 50- Expected incidence determined 2V mammography 
2002 107 Model overdiagnosis 59 invited to screening from by Poisson regression of based biennially q2 yrs 
1986-1997 (82% attendance) on age-specific incidences from starting at age 50 
Expressed as the proportional 144000 total invitations sent. Finnish cancer registry 1970- from 1986-1997. 
excess of cancers detected in Birth cohort of 1935-1939 1997 by 5 year birth cohorts. 1935-1939 birth 
screened patients with respect reported in results to contain cohort had 4-5 
to that expected in its absence -15,230 patients. screening rounds. 
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Table 9: Breast Cancer Studv Characteristics (Cont'd) ! 
Study Study Design Definition and Sample Characteristics Validation, Analysis, and Intervention 
Expression of Parameter Estimation 
Overdiagnosis 
Peeters Service Screening Overdiagnosis ~ A 30,700 women aged 35 and Nijmegen incidence I Arnhem 6 screening rounds 
1989 112 Model histologically established older living in Nijmegen, The incidence = RR of biennial 
diagnosis of invasive or Netherlands screened. mammography 
intraductal breast cancer that Incidence in this population (1975-1986) 
would never have developed was compared to incidence in 
into a clinically manifest Arnhem, a neighboring city of 
tumor during the patient's similar population that was 
normal life expectancy if no unscreened. 
screening examination had 
been carried out 
Expressed as the percentage 
increase in cancer diagnosis 
in the screened population as 
compared to the unscreened 
population 
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Table 10: Breast Cancer Study Results 
Study Reported Results Overdiagnosed Cases I 1000 Pts Overdiagnosed Cases I 1000 Cases 
Screened Detected 
Duffy Overall incidence rates equalized in yr 8-9 in Swedish Swedish Two County Trial Data: Swedish Two County Trial: 
20055 trial after control group screened. Increase in incidence 3.8 OD cases I !000 pts screened 31 OD cases I !000 screen detected cancers 
ofDCIS balanced by deficit in incidence of invasive at the 1st screen 
cancers. Gothenburg Trial Data: 3 OD cases I !000 screen detected cancers 
Sweden upper limit ofDCIS OD~l5% ofDCIS cases, 3.4 OD cases I 1000 pts screened at each subsequent screen 
1% of all tumors after exclusion of 1st screen cases 
-Frommodel: 3.l%0Datl"screen (0.1-10.9)~3.8 Gothenburg Trial 
overdiagnosed casesllOOO pts screened 42 OD cases I 1000 screen-detected cancers 
-0.3% at incidence screens at the 1st screen 
Goth upper limit ofDCIS OD~l8% ofDCIS cases, 2% 3 OD cases I l 000 screen-detected cancers 
of all tumors after exclusion of 1st screen cases at each subsequent screen 
-4.2% OD at 1 ' 1 screen (0.0-28.8) ~ 3.4 overdiagnosed 
casesllOOO pts screened 
-0.3% at incidence screens 
Overall, less than 5% of cases at prevalence screen and 
less than 1% of cases at incidence screen overdiagnosed 
Hamashima 0/E ratio for incidence of breast cancer with screening- 9 overdiagnosed cases I 1725 patients 9 overdiagnosed cases I 15 cases - 600 OD 
200628 2.41 screened ~ 5 cases I l 000 pts screened cases I 1000 screen-detected cancers 
de Koning 3% of the total incidence of breast cancer- Cannot be determined from the information 80 overdiagnosed cases I !000 screen-
200683 overdiagnosis, corresponding to 8% of screen-detected given detected cancers 
cancers 
Gotzsche About 30% overdiagnosis could be expected with Cannot be determined from the information 230 OD cases I !000 cancers diagnosed 
200686 mammography screening based on the results ofRCT's given 
-RR ~ 1.30 for Canada l980a (40-49 yo) 
-RR ~ 1.26 for Canada 1980b (50-59 yo) 
-RR ~ 1.32 for Malmo 1976 
Olsen 7.8% of screen-detected cancers overdiagnosed at the Overall incidence- 14 OD cases llOOO At the first screen: 
200688 first screen and 0.5% at the second screen. 4.8% of total patients screened 78 overdiagnosed cases I l 000 screen-
cancer diagnosis is overdiagnosed. detected cancers 
When in situ cases are excluded, rates decrease to 7.3%, At the second screen: 
which indicates- 10% overdiagnosis ofDCIS. 5 overdiagnosed cases 1!000 screen-
detected cancers 
Slight increases in overdiagnosis rates (to 
86 I !000 at 1" screen and 6 I !000 at 2"' 
screen) when sensitivity of 80% used. 
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Table 10: Breast Cancer Studv Results (cont'd) 
Study Reported Results Overdiagnosed Cases /1000 Pts Overdiagnosed Cases /1000 Cases 
Screened Detected 
Paci 2006'" Excess ratio of 4.6% after correction for lead time for Cannot be calculated without knowing the obs (corrected)- expected I observed 
both in situ and invasive cases. For invasive cases only, total number of patients screened 7906-7555.3/10,294 ~ 
excess incidence of3.2%. 34 OD cases I 1000 cancers diagnosed 
(not just screen-detected) 
Zackrisson The rate of overdiagnosis 15 years after follow up was Cannot be calculated without knowing total intervention- control/ intervention~ (3 .09 
200691 10% in women 55-69 who were not screened after the numbers of patients screened -2.81) /3.09 ~ 91 OD cases /1000 cancers 
conclusion of follow up. diagnosed (not just screen-detected) 
Paci 2004"' Overdiagnosis is less that 5% when invasive and in situ Cannot calculate this number without the Invasive + in situ cancers: 
cancers are considered together. actual number of patients screened. less than 50 OD cases /1000 cases of breast 
cancer 
Invasive only: 
22 OD cases /1000 cases of breast cancer 
(in registry) 
Zahl One third of all invasive breast cancers in 50-69 year Cannot be calculated without the actual Norway: 351 OD cases /1000 cases 
2004'02 olds are overdiagnosed. Incidence of breast cancer in numbers of patients screened. Sweden: 310 OD cases /1000 cases 
Norway increased by 54% with screening and incidence 
in Sweden increased by 45% with screening. 
Anttila In 1935-39 birth cohort: obs - expected I pts screened obs - expected I observed 
2002'07 RR of breast cancer in screened vs reference group= Cannot calculate without the exact numbers From Figure 3: 
1.18 ~ 18% overdiagnosis of observed and expected cases 4.7-4 /4.7 ~ 150 OD cases /1000 cases 
Peeters Excess of II% cases in Nijmegen for the period 1975 to Cannot be calculated II% overdiagnosis- obs- exp I obs -
1989"' 1986. For given 4 year time periods: 1.11 - I /1.11 ~ 99 OD cases /1000 cases 
1975-1978 ~ 1.30 
1979-1982 ~ 1.03 
1983-1986 ~ 1.01 
Declining rate ratios suggest a low risk for 
overdiagnosis 
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Table 11: Oualitv of Included Breast Cancer Studies I 
Quality of Study Similarity of 
Study and on Which Model Completeness of Comparison Questionable Length of Generalizability 
Overall Based or Model (overall Groups and Assumptions Made Follow up 
Quality Validated By completeness, Potential for by the Model 
sensitivity analyses) Contamination 
Duffy 2005" Fair. 2 sub optimally Fair. Good Good. Expected Assumed uniform annual 7-8 years of trial Fair. Would be 
randomized RCT's completeness. Would incidence calculated incidence of preclinical follow up is fair. better if data had 
Quality: Fair (Gotzsche citation) be better if sensitivity from the same service progressive cancers from Follow up is not a been validated by 
analyses had been screening data as the birth to age at first huge issue for this population-based 
performed to address observed incidence. screen, an exponential modeling technique. data as well. RCT's 
some of the distribution of time from also have somewhat 
assumptions. inception to these restrictive inclusion 
cancers to clinical criteria. 
symptoms, I 00% test 
sensitivity, and 
exponential incidence of 
overdiagnosed cancers 
Hamashima Poor. Based on Poor. Does not Poor. 18.5% of Assumes that all excess Poor: only I year of Fair to poor. 
200628 service screen include parameter that women had incidence is a result of follow up. Patients are 
population in Japan estimates comorbid mammography within overdiagnosis; does not volunteers in Tokyo 
Quality: Poor from 2004 to 2005. death rates. Does not previous year. take into accouut the who were almost all 
report results of possibility that some (>70%) 55-70. 
sensitivity analyses for could be earlier Exclusion of pts 
lead time/sensitivity. diagnosis of cancers that with self reported 
would have presented precancerous 
clinically. Authors disease may remove 
admit that follow up is patients with 
insufficient to correctly comorbidities. 
take lead time into Relatively small 
account. overall numbers of 
patients. 
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Table 11: Oualitv oflncluded Breast Cancer Studies (cont'd 
Quality of Study Similarity of 
Study and on Which Model Completeness of Comparison Questionable Length of Generalizability 
Overall Based or Model (overall Groups and Assumptions Made Follow up 
Quality Validated By completeness, Potential for by the Model 
sensitivity analyses) Contamination 
de Koning Fair. Nijmegen Fair. Includes Expected incidence is Poor. Assume that I 0 8 years of follow up Fair. Based on 
200683 service screen data = parameters such as modeled from Dutch percent of invasive for observed data is population-based 
observed incidence. sensitivity, lead time, service screening data breast cancers are fair. screening data, but 
Quality: Fair age aud stage. Does as well, thus the preceded by screen only 75% of invited 
not perform sensitivity potential for detectable DCIS and that patients attended 
aualyses for these contamination is low. the chance of DCIS screening. Don't 
parameters. progressing to clinical know to what extent 
disease is 90 percent. the Dutch 
Cannot determine what population 
assumptions were made represents US and 
in parameter estimation other more diverse 
from the methods section populations. 
of this paper. Unclear 
whether authors assumed 
specific distributions for 
parameters. 
Gotzsche Excellent. 7 RCT's: 2 Simplistic design. Moderate potential for Assume that all excess Fair. 7-9 years. Fair. Large trials 
200686 high quality, 5 Does not attempt to contamination. incidence is due to likely to be fairly 
suboptimally model the effect of Random sample of overdiagnosis. Some of representative of the 
Quality: Good randomized. lead time on excess 500 women in Malmo this is may be result of population. 
incidence. RCT control group lead time. Lead time However, the 
showed24% estimates of3-4 years women in the trials 
underwent for invasive breast were volunteers 
mammography during cancer would indicate who undoubtedly 
the study. this may be a small differ from the 
concern. May be a population as a 
bigger concern for whole. 
DC IS. 
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Table 11: Quality of Included Breast Cancer Studies (cont'd 
Quality of Study Similarity of 
Study and on Which Model Completeness of Comparison Questionable Length of Generalizability 
Overall Based or Model (overall Groups and Assumptions Made Follow up 
Quality Validated By completeness, Potential for by the Model 
sensitivity analyses) Contamination 
Olsen 2006'' Fair. Copenhagen Good. Good Good. Expected Assumed uniform annual Fair. Uses data Fair. Based on 
service screen data completeness. incidence calculated incidence of preclinical from a 6 year population-based 
Quality: Fair used. Sensitivity analyses from the same service progressive cancers from period. screening data. 
were performed to screening data as the birth to age at first Unclear to what 
address the sensitivity observed incidence. screen, an exponential extent these 
assumption, with very distribution of time from individuals 
little change in inception to these volunteered to be 
overdiagnosis rates. cancers to clinical screened. Unsure to 
symptoms, I 00% test what extent the 
sensitivity, and population 
exponential incidence of represents more 
overdiagnosed cancers ethnically diverse ! 
populations. 
Paci 2006" Fair. Northern Italian Fair. Models Fair. Populations are Assume an exponential Fair. Uses data with Fair. Based on 
service screen incremental cases ( # the same, but authors distribution of lead times I 0 years of follow population-based 
Quality: Fair population. of screen-detected do not state how much and lead time durations up. screening data, but 
cases in a given year) mammography of 3. 7 and 4.2 years for restricted to 
and decremental cases occurred prescreening women aged 50-59 and Northern Italy. 
( # of screen-detected in the 6 regions of 60-74 years old at screen Women volunteered 
cases that would have interest. detection. Also assume for screening. 
arisen clinically in a that predicted trends of 
given year). Includes incidence can be 
a correction of lead estimated from 
time and a sensitivity prescreening data. 
• 
analysis of different 
mean sojourn times 
that showed minimal 
change in OD. Would 
be stronger if 
sensitivity analyses 
using different lead 
time distributions had 
been performed. 
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Table 11: Oualitv oflncluded Breast Cancer Studies (cont'd 
Quality of Study Similarity of 
Study and on Which Model Completeness of Comparison Questionable Length of Generalizability 
Overall Based or Model (overall Groups and Assumptions Made Follow up 
Quality Validated By completeness, Potential for by the Model 
sensitivity analyses) Contamination 
Zackrisson Fair to Good. Based Fair. Would be better Potential for screening Assume that 55-69 yos Excellent: I 0 years Good. Large, 
200691 on high quality if sensitivity analyses of 55-69 year olds did not receive any of trial data plus 15 population-based 
(Malmo) RCT data. had been performed after the end of the mammography after the years of follow up trial that could be 
I Quality: Good with various levels of trial is high. trial, which could lead to after the trial. expected to be 
contamination of the an underestimation of generalizable to 
control group. overdiagnosis. most populations. 
Paci 2004" Fair. Based on large Fair to good. High potential for Assumes that mean Fair. 10 years of Good. Large, 
Florence service Performed sensitivity contamination; the sojourn time is 3.42 follow up within population based 
Quality: Fair screen population. analysis usiug authors do not give years and follows an service screening screening study. 
different mean sojourn any data showing low exponential distribution. study. Would be Women volunteered 
time estimates with screening rates in Like other service better with follow for screening. 
estimates ranging 1985-1989. screening models, up after the end of 
from 3-7% for assumes that no other the study period. 
invasive and in situ changes occurred from 
cancers baseliue that could have 
affected incidence (such 
as more sensitive 
screening, HR T, or 
increased surveillance) 
Zahl2004'" Fair. Based on 2 large Fair. Would be better High potential for Assume that there is no Fair. I 0 years of Fair. Large, 
service screen if sensitivity analyses contamination, baseline increase in follow up in population based 
Quality: Fair populations. had been performed because the authors incidence rates. Also do Sweden program. 5 screening study. 
that calculated OD for don't give any. not take DCIS into years of follow up However, DCIS 
different baseline account. Assume that in Norway program excluded. Women 
incidence rates. rate of reporting to the is a little short. had to accept 
nationwide cancer invitation to 
registries has not screening. 
changed (increased 
reporting could falsely 
elevate OD). Parameters 
not well defined. 
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Table 11: Oualitv oflncluded Breast Cancer Studies (cont'd 
Quality of Study Similarity of 
Study and on Which Model Completeness of Comparison Questionable Length of Generalizability 
Overall Based or Model (overall Groups and Assumptions Made Follow up 
Quality Validated By completeness, Potential for by the Model 
sensitivity analyses) Contamination 
Anttila Fair. Based on service Fair. Would be better Authors do not Asswnes that the Good. 8.5 to 11.5 Fair. Population 
2002 107 screen population in if the model reported mention the potential baseline incidence of years of follow up based; includes all 
Helsinki from 1986- overdiagnosis rates for for contamination in breast cancer has in the cohort of women in Helsinki. 
Quality: Fair 1997. all patients instead of the group of patients increased at the same interest. However, women in 
just the 1935-39 birth used to calculate the rate over the II year Helsinki are 
cohort. expected incidence. period. Another caveat probably a fairly 
is that the incidence was homogeneous 
lower than expected at population and 
the last screening round, women had to 
so the picture was still in accept invitation to 
flux and overdiagnosis screening. 
could truly be less with 
more follow up. 
Peeters Fair. Based on service Fair. Would be better Poor. Similar Main problematic Good. 9-11 years of Fair. Population-
1989112 screen population in if model compared incidence rates for assumption is that the follow up. based. However, 
Nijmegen, The age-specific incidence breast cancer pre- populations of Arnhem the women had to 
Quality: Poor Netherlands. rates in Arnhem and screening in Nijmegen and Nijmegen are similar accept invitations to 
Nijmegen. and Arnhem indicate enough to compare screening. 
that the populations incidence rates. 
I 
are similar. The Assumes that all newly 
authors do not give us diagnosed breast cancers 
an estimate of the in the registry are due to 
prevalence of screening. Reporting is 
mammography in an issue as well 
Arnhem, though, and (underreporting in 
we don't know how Nijmegen could lead to 
similar the populations lower rates of 
really are. overdiagnosis. 
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Appendix 1 
Prostate Cancer Study Selection 
Study Study Design Inclusion/Exclusion Status 
Pelzer 2007" Case Series Excluded: Pathologic definition of overdiagnosis 
Graif 2007" Case Series Excluded: Pathologic defmition of overdiagnosis 
T elesca 200725 Model fit to SEER registry INCLUDED 
data 
Postma 2007"" RCT Excluded: Does not have an explicit outcome of% 
overdiagnosis (only has % minimal cancers, but we don't know 
how many of these patients were overdiagnosed) 
Delongchamps Narrative Review Excluded: Narrative Review (no search strategy) 
200627 
Hamashima Service Screening Model INCLUDED 
200628 
Miller 2006'" Retrospective cohort Excluded: Does not focus on screening PSA-detected cases 
only. Uses a more inclusive definition of overtreatment that 
encompasses all unnecessary treatment of indolent cases. 
Parker 2006JU Competing-risks hazard INCLUDED 
model 
Pashayan 2006.< 1 Retrospective Cohort Excluded: Uses diagnostic PSA positive cases rather than 
screen positive cases 
Roemeling RCT Excluded: Does not calculate % overdiagnosis as an outcome; 
200632 speculates that increased metastasis-free survival in screened 
patients may be due to overdiagnosis 
Tsodikov 2006" Mathematical model INCLUDED 
Ciatto 200534 Service Screening Model INCLUDED 
Davidov 2004,5 Mathematical Model INCLUDED 
Kwiatkowski RCT Excluded: Does not calculate % overdiagnosis as an outcome; 
200436 states that further information from ERSPC is needed to assess 
the degree of overdiagnosis 
Tomblom 2004'' Prospective cohort study Excluded: Does not calculate % overdiagnosis as an outcome; 
states that the risk for overdetection in screening programs that 
require longer follow-up could not be assessed from this study, 
Draisma 2003" Markov Model validated by INCLUDED 
RCT and baseline incidence 
data 
Draisma 2003.<" Same study as above with a Excluded: Same as other Draisma 2003 
(MIS CAN) few extra studies reviewed 
in Discussion 
Auvin 2002'" Model based on RCT Excluded: Does not include overdiagnosis, overdetection, or 
overtreatment as an outcome. Primary outcome is lead time. 
Etzioni 2002" Computer model validated INCLUDED 
by SEER data 
Hugosson 2000" Nested Case-Control Excluded: Does not include an estimate of overdiagnosis as an 
outcome 
Etzioni 1999" Markov Model INCLUDED 
McGregor 1998 Modeling Excluded: Defines OD as the detection of cancer that, left 
untreated, would not cause death. This is a less inclusive 
definition than the definition of interest. 
Zappa 1998" Model using Monte-Carlo INCLUDED 
sampling 
Gelabert Mas 
199746 
Spanish Excluded: Spanish 
Prostate Cancer Study Selection(Cont'd) 
Study Study Design Inclusion/Exclusion Status 
Benoit 1995 Narrative Review Excluded: No systematic search strategy 
Kramer 1993"0 Narrative Review Excluded: No search strategy; overdiagnosis not an explicit 
outcome 
Slaughter 2002" Narrative Review Excluded: No search strategy; overdiagnosis not an explicit 
outcome 
Lotan 2006" Correspondence Excluded: Correspondence 
Ciatto 2006 '~ Service Screening Pilots Excluded: Overdiagnosis is not an outcome 
Graif 2006" Narrative Review Excluded: Narrative Review 
Pashayan 2006 Correspondence Excluded: Correspondence 
Ross 2005" Excluded: Overdiagnosis is not an explicit outcome 
Hessel 2004" Nested Case Control Excluded: Overdiagnosis is not an outcome; overtreatment not 
mentioned either 
Pinsky 2004 Convolution Model Excluded: Used Lung Cancer Screening Trial rather than 
Prostate Cancer Screening trial to fit model 
Sennfalt 2004" RCT Excluded: Focuses on costs; will mention in discussion section 
Ciatto 2003" RCT methods paper Excluded: Overdiagnosis not an outcome 
Ciatto 2003'" RCT methods paper Excluded: Overdiagnosis not an outcome 
Draisma 2003" Abstract of study above Excluded: Just an abstract 
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Appendix 2 
Breast Cancer Study Selection 
Stndy Study Design Inclusion/Exclusion Status 
Duffy 20055 Markov Model based on 2 RCT's, the INCLUDED 
Swedish 2 County Trial and the 
Gothenburg Trial 
Hamashima Service Screening Model INCLUDED 
200625 
Benoit 199 5"" Narrative Review Excluded: No systematic search strategy performed 
de Koning Markov Model based on service INCLUDED 
200683 screening data 
Duffy 2006'" Narrative Review Excluded: Narrative review 
Gotzsche 2006" Correspondence Excluded: Correspondence re: Zackrisson 2006 
Gotzsche 2006" Systematic Review INCLUDED** Also need to include RCT's 
Moller 2006'' Correspondence Excluded: Correspondence re: Zackrisson 2006 
Olsen 2006" Markov Model based on service INCLUDED 
screening data 
Paci 2006" Service Screening Model Corrected for INCLUDED 
lead time 
Svendsen 2006'" Service Screening Model Excluded: No explicit numerical estimate of 
overdiagnosis 
Zackrisson Follow up study of Malmo RCT INCLUDED 
200691 
Zahl2006"" Correspondence Excluded: Correspondence re: Zackrisson 2006 
Duffy 2005'~' Narrative Review Excluded: Narrative review that reports results of 
Paci 2004 and Yen 2003 
Kerlikowske Retrospective Cohort Excluded: No explicit numerical estimate of 
200594 overdiagnosis 
Moss 2005"' Narrative Review ofRCT data Excluded: No search strategy 
Paci 2005"' Narrative Review of service screens Excluded: No search strategy 
McCann2004 Service Screening Model Excluded: No explicit numerical estimate of 
overdiagnosis (actually assume no ODin model) 
Olsen 2004"' Correspondence Excluded: Correspondence 
Paci 2004" Service Screening Model INCLUDED 
Zahl2004'"" Correspondence Excluded: Correspondence re: Olsen 2003 
Zahl 2004 '" Correspondence Excluded: Correspondence 
Zahl 2004102 Service Screening Model INCLUDED 
Game 2003'" Correspondence Excluded: Correspondence 
Mandelblatt Systematic Review Excluded: No explicit numerical estimate of 
2003 104 overdiagnosis 
Olsen 2003 '"' Service Screening Model Excluded: No explicit numerical estimate of 
overdiagnosis 
Yen2003'" Markov Model based on Swedish Two Excluded: Inappropriate definition of overdiagnosis 
County RCT and service screen data (Overdiagnosis ~cases ofDCIS that are non-
progressive 
Non-progressive (DCISo) ~ DCIS which could not 
have progressed to invasive disease ifleft untreated) 
Anttila 2002 ' 07 Service Screening Model INCLUDED 
Tange 2002'"' ? Excluded: Not in English 
Hakama 199 5 '"" Comparison of pathology of screen- Excluded: No explicit numerical estimate of 
detected breast cancers with control overdiagnosis 
cancers 
81 
Breast Cancer Studv Selection(Cont'd) 
Study Study Desi2n Inclusion/Exclusion Status 
Jatoi 1995110 Narrative Review Excluded: Narrative Review 
Roselli Del Narrative Review Excluded: Narrative Review 
Turco 1993 111 
Peeters 1989112 Service Screening Model INCLUDED 
Lundgren Single arm prospective screening Excluded: No explicit numerical estimate of 
1982113 overdiagnosis 
Groot 2006 122 Cost effectiveness model of breast Excluded: No explicit numerical estimate of 
cancer overdiagnosis 
Shen 2005 12c Cost-effectiveness study Excluded: No explicit numerical estimate of 
overdiagnosis 
Kosters 200:3"" Systematic Review Excluded: No explicit numerical estimate of 
overdiagnosis 
Leiva 199§1" Cost-effectiveness study Excluded: No explicit numerical estimate of 
overdiagnosis 
Austoker 1994126 Narrative Review Excluded: Narrative Review 
Seppanen Service Screening Model Excluded: No explicit defmition or numerical 
2006 127 estimate of overdiagnosis 
Jonsson 200~ Service Screening Model Excluded: No explicit definition or numerical 
Davidov 2004""' Mathematical Model 
estimate of overdiagnosis 
Excluded: No explicit numerical estimate of breast 
cancer overdiagnosis 
Douek 2004fl" Abstract only Excluded: Abstract only 
Fracheboud Service screening model Excluded: No explicit definition or numerical 
2004 131 estimate of overdiagnosis 
HofVind 2004= Service Screening Excluded: No explicit numerical estimate of 
Olsen200F Correspondence 
overdiagnosis 
Excluded: Correspondence re: Zahl 2004 
Zah12004 13' Abstract only Excluded: Abstract only 
Paci 2004 135 Abstract only Excluded: Abstract only 
Gotzsche 
2003 136 
Abstract only Excluded: Abstract only 
Chersevani 
1998137 
Abstract only Excluded: Abstract only 
Chamberlain 
1990138 
Abstract only Excluded: Abstract only 
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